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ABSTRACT 
Glaucoma is one of the leading causes of irreversible blindness in the world, and the 
leading cause in many developing countries. It is a progressive loss of optic nerve tissue 
typically caused by increased intraocular pressure and treated by lowering the pressure. 
In developing nations where the disease is most common medications are not affordable 
and surgery is expensive and unstable. A new surgical approach and drainage device 
material that could lead to a cost effective, permanent solution were studied. A tube 
connected to an e-PTFE reservoir shunts fluid from inside the eye to the subconjunctival 
reservoir. E-PTFE was chosen because it is biocompatible and porous, while promoting 
angiogenesis and lymphangiogenesis on its surface. The surrounding vessels can carry 
the fluid back into the systemic circulation. A tangential surgical approach was evaluated 
because it could spare and protect lymphatic vessels. Recent studies have shown that 
lymphatics are important in aqueous outflow. Preliminary results showed that thee-
PTFE device could sufficiently lower IOP and that the lymphatics are potentially 
involved in aqueous outflow after surgery. These results indicate the importance of 
further evaluating a new surgical approach that addresses the role of lymphatics in fluid 
outflow from a glaucoma drainage device. 
1. INTRODUCTION 
1.1. What is Glaucoma? 
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Glaucoma is an affliction of the eye that results in the slow progressive 
degeneration of the retinal ganglion cells (RGCs) and optic nerve axons [Gupta]. It is the 
leading cause of irreversible blindness in many areas of the world, with no permanent 
treatment currently available. The main risk factor for glaucoma is elevated intraocular 
pressure (IOP), but there are other pathways and risk factors associated with glaucoma. 
Therefore, the treatment strategies for glaucoma typically attempt to lower the intraocular 
pressure. In normal eyes, the aqueous humor helps maintain the pressure necessary for 
the eye to keep its shape, while in many glaucoma patients the IOP becomes too high 
when the aqueous humor outflow mechanism malfunctions. 
Aqueous humor in the eye is produced in the ciliary body and then flows into the 
anterior chamber to provide nutrients to different cells, including those of the cornea and 
lens. The aqueous humor then exits through the conventional trabecular meshwork and 
Schlemm's canal outflow pathway or the unconventional uveoscleral outflow pathway, 
which is thought to account for 10-15% of outflow in the eye ( see Figure A.1 for the 
structure of the eye, and Appendix A for more on the types and prevalence of glaucoma) 
[Johnson 2006]. Other factors potentially involved in the development of glaucoma 
include high glutamate levels, variations in nitric oxide metabolism, and cellular damage 
from reactive oxygen species [Gupta]. Therefore, other therapies that attempt to increase 
blood flow, protect the neuronal cells in the retina, and modify gene expression in the eye 
should also be considered for the prevention of glaucoma [Vetrugno]. 
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1.2. Why is Glaucoma Treatment to Lower !OP Important? 
When left untreated, the damage to the RGCs and the nerve axons is irreparable 
and the resulting blindness is incurable. As the second cause of blindness and leading 
cause of irreversible blindness in the world, glaucoma has caused complete blindness in 
over 6 million people [Vetrugno]. Worldwide, almost 67 million people suffer from the 
disease, a number that is expected to rise to around 80 million by 2020 [Gupta]. Despite 
this, many people who are afflicted with glaucoma are not able to receive the proper care 
to prevent visual field loss. In the United States an astounding 27% of Medicare 
beneficiaries that are diagnosed with primary open angle glaucoma do not receive therapy 
in any given year [Stein]. The percent of patients who are diagnosed but do not receive 
treatment is greater among residents of metropolitan areas, Asians and Hispanics, making 
it a socioeconomic issue [Stein]. 
Additionally, in third world countries very few people who have glaucoma are 
actually treated, in large part due to the costs associated with the medications. Cost is a 
big issue with glaucoma, and it is estimated that the direct costs and lost of productivity 
of the illness costs a total of $35 billion per year in the United States [Fiscella]. Accurate 
diagnosis of glaucoma poses an issue as well since the RGCs can sustain damage prior to 
the occurrence of notable symptoms, and current techniques such as the tonometry can 
provide misleading data [Vetrugno]. It is estimated that glaucoma remains undetected in 
50% of the population prior to vision loss [Vetrugno]. There is still controversy on when 
to begin treatment for those patients with suspected early stage glaucoma. 
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Some studies show that early detection and subsequent treatment can improve 
patients' outcomes and prevent the death ofRGCs. Researchers who support early 
treatment of glaucoma believe that prolonged elevation of IOP can initiate the different 
processes involved in the destruction of the retinal ganglion cells [Schwarzt]. Once an 
elevated IOP is detected there are several factors considered in whether the patient is 
treated immediately or just observed for further progression, such as: "social-economic 
impact of a long-term treatment, likelihood that the treatment is useful for the patient, 
patient's health status, life expectancy, and patient's relative risk of developing 
glaucoma" [Vetrugno]. The prevalence of both untreated and undiagnosed glaucoma is a 
major problem, and it adversely affects a large number of people. Therefore, the main 
goal of physicians should be to look for a permanent solution to glaucoma while making 
current therapies accessible to more people in order to decrease visual loss from the 
disease. 
1.3 How is Glaucoma Treated? 
Typical methods used to treat glaucoma include pharmaceutical agents, laser 
treatments, or trabeculectomy surgery. Aqueous drainage devices, or glaucoma shunts, 
are currently only used as a secondary method of treatment because of the large number 
of complications and high failure rates [Boswell]. Even though pharmaceutical 
treatments are currently very common, a more permanent surgical solution would be 
preferred because it could improve the quality of life of glaucoma patients. Glaucoma 
drainage devices are the focus of this study because recent studies have shown their 
16 
promise for improved treatment of glaucoma in the future. In particular, the e-PTFE 
glaucoma drainage device has advantageous properties that make it a prime candidate to 
create a long-lasting aqueous outflow pathway. 
In this review, the pharmacological treatments for glaucoma will first be 
introduced briefly. Then, the promising new e-PTFE shunt along with preliminary 
studies completed on the device will be discussed. After the e-PTFE implant is 
introduced, other novel glaucoma shunts will be reviewed in detail. An in vivo rabbit 
study performed to explore a new surgical technique while ascertaining the importance of 
lymphatic drainage is then presented. The traditional trabeculectomy surgery along with 
some newer surgical techniques that could potentially replace conventional methods are 
expounded upon after the surgical method of this study. The discussion of surgical 
glaucoma treatments is followed by a review of numerous imaging methods that could 
visualize aqueous humor outflow and the corresponding imaging studies. 
1.4. Issues with Glaucoma Medications 
Drug therapy is currently the most common method used to treat glaucoma in the 
United States, but there are several issues associated with the use of glaucoma 
medications. In many chronic diseases adherence is estimated to be 75% at best, and the 
population mainly affected by glaucoma (i.e. the elderly) face even more barriers to 
proper adherence [Tsai 2009, Stein]. Glaucoma patients have more challenges, including 
hearing difficulties, impaired vision, impaired cognitive abilities, decreased health 
literacy, reliance on others to apply medication, and limited financial resources. Risk 
factors for poor adherence include complicated dosing regimen, patient-specific factors, 
provider factors, and situational factors. Safety precautions are often not observed by 
many patients when administering their medication, with only a third of glaucoma 
patients washing their hands prior to application and only a sixth using a mirror during 
application [Tsai 2009]. 
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Patient education is essential in preventing both poor adherence to treatment plans 
and poor safety habits. Unfortunately for patients with severe glaucoma, the goal of a 40-
50% reduction in IOP is difficult to reach with many of the marketed medications and 
therefore a combination of therapies or drugs with different modes of action often needs 
to be considered. In addition, there are many side effects that patients can experience 
with the use of these drugs and they can be inaccessible, especially for people in third 
world countries. 
1.5. Types of Glaucoma Medications 
There are several main classes of glaucoma medications, including beta blockers, 
prostaglandin analogs, adrenergic agents (including alpha agonists), carbonic anhydrase 
inhibitors, cholinergics, hyperosmotic agents, and investigational medications (glaucoma 
medications are discussed in more detail in Appendix B). Novel medications have 
offered improved efficacy and safety to glaucoma patients, but the search continues for a 
more permanent solution to glaucoma. An e-PTFE device that was explored in this study 
for use in glaucoma drainage surgery will be discussed in the next section. 
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2. E-PTFE GLAUCOMA DRAINAGE DEVICE 
2.1. Advantages and Disadvantages of Drainage Devices 
In developed countries, when conventional or laser surgery is not enough to lower 
the patient's IOP a device that acts as an artificial drainage pathway can be implanted to 
increase aqueous humor outflow. "Traditionally, glaucoma drainage implants have been 
reserved for patients with risk for failure with standard filtering surgery" [Nguyen]. 
Though in the past surgeons typically only used glaucoma drainage devices when 
necessary or in complicated cases, there is a growing trend towards the use of shunts for 
primary treatment as new evidence of their efficacy is continually being shown. Overall 
opinion is changing in favor of using shunts. Recently, a large experiment called the 
Tube Versus Trabeculectomy study compared the conventional trabeculectomy to the 
implantation of a shunting device and showed the benefits of using a drainage device 
[Gedde, Nguyen]. "After 1 year of follow-up, the study concluded that nonvalved tube 
surgery was more likely to maintain IOP control and avoid persistent hypotony or 
reoperation for glaucoma than trabeculectomy with mitomycin C," but "there was less 
need for medical management following trabeculectomy with mitomycin C" [Sarkisian]. 
Various complications can result with the surgical implantation of glaucoma 
drainage devices, including hypotony, diplopia, proptosis, tube erosion, failure, 
endophthalmitis, and visual loss. The most persistent complications associated with 
glaucoma shunts but not with conventional surgery are those related to cornea, including 
corneal endothelial loss or even corneal decompensation [Hau]. In many cases glaucoma 
drainage devices are not made from a biocompatible material, so the body sequesters the 
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implant with a fibrous response and surrounds it with a fibrous capsule. This fibrous 
capsule does not allow diffusion or passage of the aqueous fluid, and the shunts fail. 
Though tube blockage from blood, fibrous membranes, vitreous, inflammatory debris, or 
iris tissue is a cause of failure, inadequate capsular diffusion more commonly the reason 
why some shunts fail [Burchfield]. The e-PTFE shunt was designed to address the issues 
of improper immune response and low capsular diffusion. 
2.2. Why e-PTFE? 
In response to the clinical challenges that glaucoma poses a valve/shunt using a 
porous polymer, expanded polytetrafluoroethylene (e-PTFE) has been proposed (see 
Figure 2.1 ). It is thought that fluid flows from the reservoir and out through the venous 
channels surrounding the valve to lower the IOP. Through several studies e-PTFE has 
been shown to be very inert in the body, non-immunogenic, biodurable, and a material 
that when denucleated of trapped air in the appropriately sized pores will promote 
vascular growth [Schwartz]. Experiments have shown that e-PTFE denucleated prior to 
implantation has improved tissue incorporation, decreased thrombogenicity, and 
increased neovascularization when compared to conventional drainage devices [Boswell]. 
Though results of previous clinical studies with the e-PTFE device were not markedly 
different from previous aqueous drainage devices, they showed a lowering ofIOP and 
room for improvement [Kim 2003]. 
Additionally, recent experiments with porous e-PTFE membranes around 
previous valve designs showed an altered tissue response indicating less fibrous growth 
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and enhanced vascularization [Decroos]. "Several groups have hypothesized that 
increasing the number of vessels in the tissue surrounding the implant will lead to 
improved and prolonged device function" [Schwartz]. Neovascularization is thought to 
have a huge benefit because the new vessels can bypass the fibrous capsule surrounding 
the device. In glaucoma drainage devices, the new vessels could act as collector channels 
to help flush fluid away from the subconjunctival bleb, preventing the back pressure in 
the reservoir and allowing for more efficient aqueous outflow. Typically, aqueous 
drainage devices are not successful because of fibrous capsule growth around the 
drainage device inhibiting aqueous humor outflow. However, evidence shows that there 
are no advantages to using antifibrotic agents with the currently available shunts, which 
makes angiogenesis around the device even more important [Minckler]. The improved 
vascularization and decreased immune response seen near the e-PTFE device could 
translate into improved patient outcomes, and it is therefore a novel device that should be 
considered for use in future glaucoma treatment. 
10 
Figure 2.1 Image showing the e-PTFE glaucoma drainage device [Kim 2003] 
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2.3. Preliminary Flow Studies with the e-PTFE Device 
Additional information about the e-PTFE glaucoma implant will be extremely 
helpful once it reaches the clinical trial stage in the United States. A preliminary 
experiment was completed to characterize several flow properties of the e-PTFE 
glaucoma shunt. To achieve this goal, multiple flow studies were performed on both the 
I-sided and 2-sided e-PTFE glaucoma shunt. The flow rate was also measured at 
different pressures and at different bovine albumin protein concentrations. The flow rate 
studies were performed on two different e-PTFE I-sided shunts (labeled as la and lb) 
and two different e-PTFE 2-sided shunts (labeled as 2a and 2b) purchased from Impra, 
Inc. (Tempe, AZ). The setup for the experiment included a syringe connected to a tube, 
with either an 18 gauge needle to attach over the end of the e-PTFE shunt or a 28 gauge 
needle to attach inside the end of the e-PTFE shunt. Once the water or bovine albumin 
solution was poured in the syringe, it flowed down the tube because of the water pressure 
head, and the hydrostatic pressure was set to different values by changing the height of 
the syringe above the drainage device. The solution was allowed to flow through the 
device onto a petri dish, and the amount of liquid was weighed every minute to calculate 
the overall flow rate. 
The results of the experiments conducted showed several interesting phenomena 
(Figure 2.2). First of all, though the flow rate through the shunt did decrease as the 
hydrostatic pressure decreased, it typically did not do so in a linear fashion. In fact, the 
relationship between pressure and flow rate, as shown in previous flow studies and 
several of the current flow studies, seemed to be fairly exponential in nature. 
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Additionally, depending on the starting pressure of the experiments, the relationship 
between the flow rate and pressure seemed to vary greatly. For example, when the flow 
rate was measured at extremely high pressures with a steadily decreasing pressure 
interval, the relationship between pressure and flow rate appeared more linear in nature. 
The results of the flow experiments at different pressures seem to indicate that the pore 
size of the e-PTFE is extremely flexible, and can vary depending on the pressure that is 
exerted upon the polymer. In order to verify these flow rates, more standard flow 
experiments should be done with the same device, the same starting pressure, and the 
















4 1 .. 16 
Pressure Vs. Flow rate 
_.__ Previous S d_ 
b I rial I !' l l'E ~ 
- e- T 'al 2 l"TFE l 
- Ina!' !'fl'Ela 
--+-- ial I PTFE lo 
0 4 6 40 44 4R 
Water Pressure (mmHg) 
Figure 2.2 Graph showing the flow rate versus pressure for the I-sided e-PTFE shunts 
(1 a and 1 b, red) and the 2-sided e-PTFE shunts (2a and 2b, black) 
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Flow rate studies were completed on both the 1-sided and 2-sided e-PTFE shunt 
to evaluate the differences between the different porous surface areas (Figure 2.2). 
Though in general it seemed as if the flow rate through the I-sided implant was lower, it 
was difficult to verify statistically with the variable results that were obtained. Another 
experiment was completed in which the flow rate through the e-PTFE shunt was 
measured at different bovine albumin protein concentrations (bovine albumin solid 
powder was purchased from Sigma-Aldrich). The concentrations tested were chosen 
based on data showing that the protein concentration can be around 1 g/L in patients with 
glaucoma, and even up to 10 g/L in cases of inflammation [Prata]. The data from this 
experiment is valuable because the protein concentration in the inflamed eye of glaucoma 
patients is much greater than in nonnal aqueous humor, so determining how the protein 
concentration affects the flow characteristics of the e-PTFE shunt is useful. 
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Figure 2.3 Graph showing how the pressure changes with flow rate at different bovine 
albumin concentrations in both the 1 a glaucoma shunt (black) and 1 b glaucoma shunt 
(red) 
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The results of the protein concentration versus flow rate experiment show a clear 
decrease in flow rate as the protein concentration was increased, with the effect leveling 
off at higher protein concentrations (Figure 2.3). Though the results are somewhat 
unexpected due to the relationship between the pore size in the e-PTFE and the bovine 
albumin protein size, it seems as if the protein molecules still occlude the pores enough to 
affect the flow of liquid though them. Despite the lower flow rates with increased protein 
concentrations, the flow rates still exceed the necessary outflow in the eye. Therefore, in 
practical use the increased protein concentrations are not expected to detrimentally affect 
the outflow in patients once the device is implanted, though the different liquid densities 
should be considered more carefully in future flow rate experiments. In conclusion, it 
was shown that the flow rate though the valve decreased with increasing protein 
concentration and that the pore size in addition to the flow rate could be affected by 
pressure. Future studies with the device should also look at the reservoir pressure of the 
bleb, since this decreases the outflow in glaucoma drainage devices. The backpressure 
from the bleb could be taken to account by measuring the flow rate when there is a 
hydrostatic pressure on the device itself, which could be mimicked by placing the device 
at a specific depth in a known amount of liquid. 
The e-PTFE device is a novel drainage implant with many benefits that could be 
advantageous for the treatment of glaucoma. Though other implants do show some 
promise, there are many aspects of the e-PTFE device that make it a potentially more 
effective option. Some of the other new drainage devices currently on the market will be 
discussed in the next section. 
25 
3. AQUEOUS DRAINAGE DEVICES 
3.1. Standard Drainage Devices and Success Rates 
There are two major types of glaucoma shunts: valved and non-valved. "The 
rational of a valve device is to provide a minimal amount of flow resistance, preventing 
hypotony by creating a 'cut-off switch' to stop flow when a certain IOP is reached" 
[OphthalmologyWeb]. There is no consensus on which conventional device has the best 
IOP control with the least amount of complications because studies show conflicting 
results. However, it has been shown through several experiments that a higher surface 
area offers lower IOP values, at least in the short term. "The overall success rate among 
five implants studied, namely, Molteno single and double plate, Baerveldt, Ahmed, and 
Krupin implants, was between 72% and 79%. All five implants decrease the pressure by 
51-62%. There were no statistically significant differences in either the percentage 
change in intraocular pressure (IOP) or the overall surgical success rate among the five 
implants." [Shaarawy] More specific information about these conventional aqueous 
drainage devices can be found in Appendix D. 
Comparing different success rates following glaucoma surgery is difficult because 
the definition of success rate changes between experiments and there are many 
confounding factors such as the use of medications, the equipment used, the surgeons, 
prior glaucoma surgery, and the patients themselves. Though controversy still exists on 
whether or not shunts are preferable to conventional trabeculectomy, many new devices 
are under development that could be groundbreaking therapies for glaucoma. Also, it 
could be argued that there is more room for innovation and improvement with glaucoma 
drainage devices as opposed to conventional surgery. Glaucoma drainage devices 
potentially hold more promise for future glaucoma treatment than conventional surgical 
methods, despite some of their disadvantages. Several new devices and implantation 
approaches are introduced in this section. 
3.2. Solx Device 
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The Solx device is a gold microwafer shunt implanted ab extemo from the scleral 
side that shunts aqueous humor from the anterior chamber to the 
suprachoroidal/supraciliary space (see Figure 3.1). The gold micro shunt is thought to 
increase uveoscleral outflow, which in turn would decrease IOP. The device is very thin 
and made from 24-karat gold, with 19 tubules (10 are closed and 9 are open) to facilitate 
aqueous humor outflow [Stamper 2011]. "Gold is known to be biocompatible, with no 
known long-term toxicity in the eye" [Melamed]. A benefit of this device is that the 
closed channels in the device can be opened using a titanium-sapphire laser beam to 
increase aqueous outflow. 
In addition, the Solx device avoids the formation of a filtration bleb along with 
the associated complications. It was approved by the FDA in 2008 and is currently in 
clinical trials. One pilot study showed that 79% of patients achieved an IOP between 5 
mm Hg and 22 mm Hg with the gold micro shunt, and 13% did not need glaucoma 
medication [Melamed]. On average, patients saw a 44% reduction in IOP, an average 
IOP of 15.4 mm Hg, and an average of 0.4 medications at their last follow-up [Stamper 
2011]. Several complications seen with this device were synechia, hyphema, and retinal 
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detachment. The results of preliminary studies with this device are very encouraging, 
and the new suprachoroidal surgical approach may be better than the subconjunctival 
surgical approach. However, though gold is biocompatible this device would not give the 
same flexibility in movement as the e-PTFE device. 
Figure 3.1 Solx device implantation method in the suprachoroidal space (left) and size 
comparison with a quarter (right) [SOLX Inc.] 
3.3. Ex-PRESS Shunt 
The Ex-PRESS shunt was approved for use in glaucoma drainage surgery in 
2002, and is made out of 316L stainless steel with a conductive oxide layer that helps 
inhibit an inflammatory response [De Feo]. The device has a beveled, rounded tip, with a 
projection at the back end to prevent it from exiting the eye, and a disk-like flange at the 
other end to prevent it from migrating into the anterior chamber [Mermoud]. The shunt is 
implanted in a procedure similar to a trabeculectomy, and it bypasses the normal aqueous 
outflow pathway by creating a channel from the anterior chamber to subconjunctival 
space [Francis 2011]. See Figure 3.2 for the placement and design of the Ex-PRESS 
device. Previous studies on the safety of this device have shown that it induces a 
favorable healing response in human eyes, with the formation of a thin, fibrous capsule 
around the device and no scar formation or inflammation [Nyska, De Feo]. 
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A study on the effectiveness of this implant showed it had a success rate ( defined 
as IOP less than 21 mm Hg) of 76.9% at the patient's last visit (usually a 3 year follow-
up) [Traverso]. Another study showed it had a success rate (defined as IOP between 5 
and 21 mm Hg with no additional surgery necessary) of 84.3% at 15 months with 
implantation of the Ex-PRESS device [Maris]. As with other shunt procedures, there is 
the risk of trauma to the cornea or iris and it still requires the use of antifibrotics or other 
glaucoma medications. In addition, though the stainless steel has an oxide layer to reduce 
inflammation, there would still be issues with inflammation, fibrotic growth, and 
surrounding tissue necrosis. These same issues are not encountered with the use of the e-
PTFE shunt. 
Figure 3.2 Placement of the Ex-PRESS shunt in between the anterior chamber and 
subconjunctival bleb (top), and design of the Ex-PRESS shunt (bottom) [Traverso] 
3. 4. !Stent Implant 
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An L-shaped nonferromagnetic titanium tube called the iStent is another novel 
device that can be used in glaucoma filtration surgery. "The trabecular micro-bypass 
stent is designed to create a permanent opening from the anterior chamber into 
Schlemm' s Canal" [Francis]. The shunt is designed to fit and stay in Schlemm' s canal, 
and one end is pointed for insertion into the canal while the other end has a half cylinder 
over it to prevent blockage of the tip (see Figure 3.3 for the iStent shunt design). 
A very small pilot study showed that the device "warranted further investigation," 
though the data was limited [Francis]. Another study conducted showed that "compared 
with cataract surgery alone, implantation of the iStent concomitant with cataract 
extraction significantly increased trabecular outflow facility, reduced IOP, and reduced 
the number of medications at 1 year" [Fernandez-Barrientos]. It is difficult to elucidate 
the exact effect of the iStent alone, however, because it was usually combined with 
cataract removal, a surgery known to lower IOP. 
3.5. CyPass Shunt 
Lumen 
120 µm Retention 
Arches Self -Trephining 
Tip 
Figure 3.3 Design of the iStent Implant [Harris] 
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The CyPass is another novel shunt that can be used for the treatment of glaucoma 
(see Figure 3.4 for a size comparison between the CyPass device and a dime). It is a tiny 
"tube-like device made of a highly biocompatible material that is inserted into the 
suprachoroidal space just above the ciliary face across the anterior chamber" [Stamper 
2011]. This technology has been available in Europe since 2009, but is "only available in 
the U.S. through the COMPASS clinical study" [Transcend Medical]. Though the 
preliminary studies are currently not published, some results are quoted that show 
patients having an average IOP of 13 mm Hg, a 35% reduction in IOP, and an average of 
0.9 medications at the last follow-up [Stamper 2011]. 
CyPass Mioro-Stent 
Figure 3.4 Size comparison between the CyPass implant and a dime [Transcend 
Medical] 
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In order to improve surgical outcomes certain factors such as placement and 
surgical method need to be considered. Recent studies have shown the importance of the 
lymphatic networks near the eye following drainage surgery, so developing a surgical 
technique that preserves the lymphatic networks near the eye could be very beneficial. 
An in vivo rabbit study to begin assessing the role of the ocular lymphatic channels in 
aqueous humor outflow was performed. The rabbit study looking at a new surgical 
approach is expounded upon in the next section. 
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4. IN VIVO RABBIT STUDY 
4.1. When is Glaucoma Surgery Necessary? 
Despite the challenges with conventional filtration surgery, there are numerous 
reasons why an improved surgical technique as a first line of therapy would be beneficial. 
As stated previously, most patients throughout the world who have glaucoma do not have 
access to drugs or cannot afford them. Therefore a safe, permanent surgical procedure 
that could be performed with minimal equipment is needed. In addition, if surgery could 
be used as the sole treatment for glaucoma there would be no issues with patient 
adherence and the onetime cost would make therapy much more accessible. However, if 
glaucoma surgeries were to be performed in third world countries, there are some 
practical aspects to consider. For example, a system would need to first be in place to 
properly train surgeons in order to prevent infection and other complications. These 
challenges are not insurmountable. The surgical method explored in this study could be 
easier to perform and more effective, making it accessible to more glaucoma patients. 
4.2. Introduction of Experiment 
The main goal of this experiment was to identify a surgical technique that 
preserves the lymphatic channels near the eye. Though in normal eyes there does not 
seem to be a connection between the lymphatics of the conjunctiva and aqueous humor 
outflow, this appears to change drastically after glaucoma surgery [Singh]. The 
conjunctival lymphatics play a major role in aqueous humor outflow once surgery has 
been performed, and therefore it is extremely essential that the surgeon protects these 
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lymphatic networks during surgery [Yu]. Up until very recently there has been very 
limited data in the literature concerning the conjunctival lymphatics along with its role in 
aqueous humor outflow [Singh]. 
The lymphatic networks of the eye should definitely be studied in more detail, 
especially since their importance has recently been highlighted. In previous studies, the 
lymphatic channels near the eye have been shown to run perpendicular to the limbus [Yu, 
Singh]. Thus, in this experiment we will perform glaucoma drainage surgery by making 
an incision perpendicular to the limbus (called vertical in this experiment) in one group 
and an incision parallel to the limbus ( called horizontal in this experiment) in another 
group. In this way we hope to compare the two surgical methods and show that the 
outcome of the surgery is drastically improved when the surgical incisions are completed 
in parallel to the lymphatic networks of the eye as opposed to directly across. Our 
hypothesis is that the surgery employing the vertical incision will more effectively 
preserve the lymphatic networks when compared with the horizontal surgery. 
4.3. Justification of Experiment 
A new surgical method using a microfistula shunt was employed by Yu et. al in 
both rabbits and monkeys. In the animals where lymphatic drainage pathways were 
clearly visible, the aqueous humor drainage pathway remained effective for a longer 
period of time. Therefore, the authors clearly showed the importance of the conjunctival 
lymphatic network in the overall success of glaucoma drainage surgery. Due to the nature 
of this experiment, and after an extensive literature search, it was concluded that 
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performing this experiment using a computer model or in vitro techniques would not 
yield the desired information. We are exploring a surgical method and its effects on an 
entire physiological system. Therefore, in vitro methods would not accurately show the 
interaction between the different tissue types and their response as a unit to the trauma of 
surgery. Because of the complexity of the system, and the unknown factors, creating a 
computer model to accurately predict the behavior of the eye is currently impossible. 
In planning this experiment we had considered using animals smaller than rabbits, 
such as rats or mice. However, since we would like to apply the information obtained 
from this study to humans we decided to use an animal model that more closely 
approximates a human eye. Therefore rabbits were chosen since the size and structure of 
a rabbit eye lends itself more easily to glaucoma drainage surgery and comparison with 
human eyes. There is also a rabbit model of glaucoma that could be very useful in this 
study, while there is no rat or mouse model of glaucoma. Potential candidates for 
glaucoma models that could be used are the genetically predisposed buphthalmic rabbits 
or rabbits that have glaucoma induced by alpha chymotrypsin A [Gelatt]. Additionally, 
in practice performing this type of glaucoma filtration surgery on an animal such as a 
mouse would be extremely difficult and impractical. Fluorescent imaging of vascular 
and lymphatic networks would also pose more of an issue in the rat and mouse models 
than in the rabbit model. 
Though this work partially duplicates a previous study, the surgical techniques 
that we will test are different. In the previous study the researchers performed a very 
precise glaucoma drainage surgery employing a microfistula shunt. For general use, this 
method would require the attention of an extremely skilled surgeon along with very 
expensive equipment. The importance of the surgical techniques that we tested is that 
they are accessible to more people and will be able to be performed by any opthalmic 
surgeon. The method for glaucoma drainage surgery that we hoped to identify will be 
extremely practical in its application. 
4. 4. Materials and Methods 
Materials 
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Five rabbits were used for this pilot study. The rabbits were purchased from 
Harlan laboratories, and were acclimated to the University Animal Care Center for one 
week before experimentation. Trypan blue dye bought from Sigma-Aldrich was used in 
the imaging portion of the experiment. A small section ( ~ 2 mm) of a silicone tube was 
used as a glaucoma shunt. Various microsurgical tools, opthalmic knifes, speculum, 
balanced salt solution, 23 gauge needles, and absorbable adle-vicryo sutures were used 
during surgery and imaging. Everything used during surgery was either heat sterilized in 
an autoclave (metal objects) or chemically sterilized using ethylene oxide gas (silicone or 
plastic). During surgery a glass bead sterilizer was used to keep the surgical tools sterile. 
Surgery 
NIH guidelines for the care and use of laboratory animals will be observed 
throughout the study (NIH Publication #85-23 Rev. 1985). In addition, this procedure 
was performed under IACUC protocol #10-241 at the University of Arizona Animal Care 
Center. Rabbits were anesthetized using an intramuscular injection with 0.5 cc/kg of a 
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rabbit mix (solution mixed is 2 mL of 10 mg/mL acepromazine, 5 mL of 100 mg/mL 
ketamine, and 8 mL of 20 mg/mL xylazine ). Betadiene was sprayed around the eye, 
which was held open with a wire eyelid speculum. Proparacaine drops (1-2 drops) were 
administered to the surface of the eye, and then epinephrine was put onto the eye with a 
cotton swab. Either a vertical or horizontal incision was made in the conjunctiva using a 
super sharp ophthalmic knife, and then the flap was opened farther by using forceps to 
hold it up and then cutting with scissors. After, a stab incision was made from the 
vertical or horizontal incision near the limbus to the anterior chamber. 
The silicone tube was then inserted into the new pathway made to the anterior 
chamber. Once the silicone tube was in place, and drainage of aqueous humor was 
visible, the end of the silicone tube was cut down to size. Balanced salt solution was 
injected in the anterior chamber to prevent collapse of the anterior chamber. The 
conjunctiva} flap was then closed with a vicryl suture, the speculum was removed, and a 
drop of zymar was put on the eye. Then, the eyes were treated with a topical antibiotic 
and analgesic for 4 days post-operatively. The antibiotic used was neomycin ointment 
while the analgesic used was proparacaine. IOP measurements were made with a 
tonopen (Reichert) periodically throughout the study. 
Histology 
After five weeks, the rabbits were euthanized and the eyes were removed and 
fixed for histological examination. Paraffin sections 5 µm thick were stained with 
hematoxylin and eosin for evaluation of overall tissue organization. Other serial sections 
were stained using immunohistochemical staining. The CD34 antibody was used to stain 
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vascular endothelium, in order to be able to count the number of nearby vessels. Then, 
CD3 l was used to stain both the vascular and lymphatic endothelium to count the total 
number of vessels. The D2-40 antibody was also used to specifically stain the lymphatic 
endothelium. All of the primary antibodies were mouse antibodies, and all the secondary 
antibodies were anti-mouse rabbit antibodies. The immunohistochemical staining was 
performed in Dr. Raymond Nagle's pathology laboratory at the University of Arizona 
Cancer Center. 
Imaging of lymphatics and vasculature 
During the imaging studies, the rabbits were anesthetized using an intramuscular 
injection with 0.5 cc/kg of a rabbit mix (solution mixed is 2 mL of 10 mg/mL 
acepromazine, 5 mL of 100 mg/mL ketamine, and 8 mL of20 mg/mL xylazine). Then, 
the trypan blue was administered using a 23 gauge needle in the anterior chamber of all 
of the eyes, and into the subconjunctival tissue of several eyes (rabbits 11-03 and 11-05). 
Using a technique similar to that previously described by Seetner and Morin, trypan blue 
was injected into the subconjunctival tissue to create interstitial tissue fluid, which then 
can drain through the lymphatics. A 23-gauge needle was used to inject sterile trypan 
blue to form a small subconjunctival blister just below the conjunctiva! epithelium [Yu]. 
The pool of trypan blue was be observed in order to evaluate if it remained stagnant, 
meaning lack of lymphatic drainage, or if it spread away from the blister, indicating the 
existence oflymphatic drainage and showing the distinct branch-like tributaries. The 
rabbits were then observed for several hours after injection into the anterior chamber and 
subconjunctival tissue. The day after the imaging studies were completed, the rabbits 












Figure 4.1 Experimental Setup 
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Five rabbits were used during this study, and surgery was performed in the left 
eye of each rabbit while the right eye of each rabbit was left as a control (Figure 4. l ). 
Two different types of surgery were completed to test their effects: vertical incision near 
the limbus and horizontal incision near the limbus. Rabbit 11-01 had a vertical incision, 
rabbit 11-02 had a vertical incision, rabbit 11-03 had a vertical incision, rabbit 11-04 had 
a horizontal incision, and rabbit 11-05 had a horizontal incision. 
4.5. Imaging Study Results and JOP Results 
Several pictures were taken during the surgery to show the method of 
implantation used in this study for the glaucoma shunt. 
Figure 4.2 Image showing the placement of the silicone tube in a rabbit eye during 
surgery, from the limbus into the anterior chamber, using forceps 
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After surgery, the IOP of the rabbits was measured at 9 days (Table 4.1) . The 
IOP measurements show that the surgery was effective in lowering IOP. With a visual 
inspection, at 9 days the glaucoma shunts and bleb formation could be seen in most of the 
rabbits. The IOP was also measured prior to perfonning the imaging studies. These 
results showed that the pressure of the rabbit ' s eyes greatly decreased after being put 
under anesthesia, ranging from 5 mm Hg to 18 mm Hg. In addition, at 5 weeks the 
shunts were not visible when the eyes were observed. 
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11-01 21 18 Small bleb, hard to see tube in anterior chamber 
11-02 24 19 Tiny bleb, can see tube in anterior chamber 
11-03 29 26 Tube is in place and visible 
11-04 25 21 No bleb, but the tube is visible 
11-05 23 19 Shallow bleb, can see tube in anterior chamber 
Table 4.1 IOP data from the rabbits (in mm Hg), 9 days following surgery 
Imaging studies were performed on the rabbits at 5 weeks following the surgery, 
prior to euthanization (Figure 4.3). After the trypan blue was injected into the anterior 
chamber of the rabbits, they were observed for several hours . The perfusion out of the 
anterior chamber was not visible in specific blood vessels, but the sclera appeared to be a 
diffuse blue color in the eyes on which surgery was perfonned (Figure 4.4). 
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Figure 4.3 Anterior chamber and subconjunctival bleb filled with trypan blue at 5 weeks 
following surgery, during the imaging studies on the rabbits 
Figure 4.4 Comparison of control right eye with a subconjunctival bleb (left) to a 
surgically treated left eye with a blue-tinted sclera (right) 
Following euthanasia, another imaging study was performed to ensure 
visualization of trypan blue perfusion through the vessels since it was difficult to see in 
the initial imaging study. The setup for the continuous perfusion imaging study was: a 




the anterior chamber or subconjunctival space of the rabbit eye. The pressure was 
adjusted by changing the height, and was set between 15 and 20 mm Hg to mimic 
physiological pressure. With this setup, perfusion of the trypan blue into surrounding 
vessels was visible. It appeared that some vessels that filled with trypan blue were 
conjunctival lymphatics because they were distinct from some of the visible surrounding 
blood vessels, and they moved when the conjunctiva was manipulated. Pictures showing 
perfusion in the rabbit eyes during the second imaging study are shown from Figure 4.5 
to Figure 4.9. 
Figure 4.5 Image showing perfusion of trypan blue in the right eye of rabbit 11-01 
(control) 
Figure 4.6 Image showing perfusion of trypan blue in the left eye of rabbit 11-01 
(vertical incision) 
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Figure 4.7 Perfusion of trypan blue in a subconjunctival bleb in the right eye of rabbit 
11-03 ( control) 
Figure 4.8 Image showing perfusion of trypan blue in the right eye of rabbit 11-04 
( control) 
Figure 4.9 Image showing perfusion of trypan blue in the left eye of rabbit 11-04 
(horizontal incision) 
4. 6. Histology Results 
The hemotoxylin and eosin stained histology slides showed the overall tissue 
organization in the rabbit eyes. Tissue sections were taken in cross section from the 
limbus, near the border of the sclera and cornea. Figures 4.10 to 4.13 show some H&E 
histology slides taken from the left and right eye of rabbit 11-04. Certain anatomical 
structures of the eye can be seen in the H&E slides, including the ciliary process, the 
conjunctiva, the sclera, and the lens. The histology slides did not show any conclusive 
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difference between the different types of surgery or between surgically treated eyes and 
control eyes. However, there is evidence of lymphocyte infiltration into the tissue, as can 
be seen by the potential lymphatic cells (tiny purple circles) between the cells in the 
tissue of the sclera and the conjunctiva. 
Figure 4.10 Histology sections (stained with Hemotoxylin and Eosin) from the right eye 
of Rabbit 11 -04, at 2x magnification 
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Figure 4.11 Histology sections (stained with Hemotoxylin and Eosin) from the right eye 
of Rabbit 11-04, at l Ox magnification 
Figure 4.12 Histology sections (stained with Hemotoxylin and Eosin) from the right eye 
of Rabbit 11-04, at 20x magnification 
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Figure 4.13 Histology sections (stained with Hemotoxylin and Eosin) from the left eye of 
Rabbit 11-04, at 20x magnification 
Staining to see the blood vessels was also performed using the CD34 antibody, 
but the antibody did not function properly because it did not stain the positive control. 
Therefore, the results of that staining were invalid and the staining needs to be repeated. 
In addition, immunohistochemistry staining was completed with the lymphatic vessel 
specific D2-40 primary mouse antibody along with the lymphatic and blood vessel 
specific CD3 l primary mouse antibody. A secondary anti-mouse rabbit antibody was 
used to detect the presence of the primary antibody, via a connected peroxidase enzyme 
that turns a reddish-brown color in the presence of a substrate. 
Due to the fact that a secondary rabbit antibody was used, there was a great deal 
of background staining. Compared with the positive controls, which show very specific 
binding to the vessel endothelium (see Figure 4.14 and Figure 4.16), the stained samples 
show a lot of excess staining (see Figure 4.15 and Figure 4.17), and the negative controls 
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also show staining where they should not (see Figure 4.18). Therefore, per my 
conversation with the pathologist Dr. Raymond Nagle at the Arizona Cancer Center who 
viewed the slides for scoring, no conclusive statement could be made regarding the 
presence of lymphatic or blood vessels. Staining with a more specific antibody should be 
completed in the future to verify the presence of lymphatic vessels. A secondary 
antibody that is not from a rabbit should be used in the future when staining rabbit tissue. 
Figure 4.14 Histology sections stained with CD31 blood and lymphatic vessel-specific 
antibody from a human placental tissue positive control, 20x magnification 
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Figure 4.15 Histology sections stained with CD3 l blood and lymphatic vessel-specific 
antibody from the right eye of Rabbit 11-04, 20x magnification 
Figure 4.16 Histology sections stained with D2-40 lymphatic vessel-specific antibody 
from a human placental tissue positive control, 20x magnification 
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Figure 4.17 Histology sections stained with D2-40 lymphatic vessel-specific antibody 
from the right eye of Rabbit 11-04, 20x magnification 
Figure 4.18 Negative control stained with the secondary anti-mouse rabbit antibody from 
the right eye of Rabbit 11-04, 20x magnification 
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4. 7. Discussion 
The glaucoma drainage surgery and subsequent imaging showed that lymphatics 
are potentially involved in the outflow of aqueous humor after surgery. The lower IOP in 
the eyes with the glaucoma drainage devices proves that the surgery successfully reduced 
the IOP. During the first imaging study, while the rabbits were still alive, perfusion of 
trypan blue into the surrounding vessels was not visible. However, the sclera in the 
surgically manipulated eyes appeared to be a diffuse blue color for a couple hours after 
the initial injection of the trypan blue into the anterior chamber. The blue tint to the 
scleral tissue seems to suggest that there is outflow from the anterior chamber into the 
subconjunctival space (though the dye did not stay in one contained bleb ), bypassing the 
traditional aqueous humor outflow pathways. There are several reasons why specific 
vessels may not have been highlighted by the trypan blue. 
One reason for the lack of proper perfusion could be that the natural aqueous 
production in the rabbits' eyes could have diluted the dye a great deal, making it not 
concentrated enough to show up clearly. In addition, when the rabbits were under 
anesthesia their IOP was extremely low, which could have prevented aqueous humor 
outflow until the pressure returned to normal. The shunts had most likely scarred over 
because they were not visible. If the shunts were not functioning properly, then the 
aqueous humor perfusion would be difficult to see. All in all, the initial in vivo imaging 
study with trypan blue shows diffusion into the subconjunctival space in eyes that 
underwent placement of a glaucoma implant, which makes sense in light of the fact that 
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the new drainage pathway created by the surgery shunts aqueous humor from the anterior 
chamber to a bleb underneath the conjunctiva. 
After the rabbits were euthanized, trypan blue was perfused at a constant pressure 
into the anterior chamber of all five rabbits, and into the subconjunctival space of both 
eyes of rabbit 11-03. The hypothesis of this experiment was that the lymphatic networks 
are better preserved when surgery is performed along the lymphatic networks instead of 
directly across the lymphatic networks. Since the lymphatic networks have been shown 
to run perpendicular to the limbus, the rabbits that underwent surgery with a vertical 
incision should show better lymphatic perfusion during these flow rate studies. Rabbits 
11-01, 11-02, and 11-03 all had a vertical surgery (perpendicular to the limbus) while 
rabbits 11-04 and 11-05 both had horizontal surgery (parallel to the limbus ). 
Though the results from the pictures are not entirely conclusive, there does seem 
to be a pattern showing that the lymphatic networks are cleaved more during the 
horizontal incision surgery. In all of the right eyes, several different randomly oriented 
vessels are visible with trypan blue, some of which seem to collect near to the limbus 
(Figure 4.5 and 4.8). The vessels filled with trypan blue seen in the photos of the right 
eyes may be lymphatics, as there are a couple instances where separate blood vessels are 
also visible (Figure 4.8) or the structure is indicative oflymphatics (Figure 4.5). 
Therefore, the images of the control eyes potentially show how lymphatic perfusion in 
normal eyes would appear. In all the left eyes of the rabbits that underwent vertical 
incision surgery, there was clear evidence of normally arranged, intact lymphatics. 
Additionally, in rabbit 11-01 the potential lymphatic networks appear very dark and 
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concentrated around one particular area, hinting that those particular lymphatic channels 
may have been near the shunt and utilized for increased aqueous humor outflow (Figure 
4.6). 
In contrast, the dye in each left eye of the rabbits that went through horizontal 
incision surgery did not seem to perfuse into distinct collector vessels in the same manner 
as the vertical incision group. The trypan blue is visible in the left eyes of rabbits 11-04 
and 11-05 as a darker blue coloring over sections of the sclera, hinting that the lymphatics 
were not kept intact during surgery (Figure 4.9). Without whole lymphatic vessels, the 
dye could diffuse underneath the conjunctiva instead of being taken up by unaffected 
collector vessels. The results that show potential lymphatic activity need to be further 
verified with immunohistochemical staining, which needs to be repeated due to the 
inactive antibody or excessive background staining. The H & E staining did not show 
any visible difference between the tissue of the surgically treated eyes and the control 
eyes or any difference between the types of surgery. However, the staining did show 
potential lymphatic infiltration in almost all of the samples, indicating that the lymphatics 
do play a role in the functioning of the eye. More work needs to be done to verify that 
the lymphatic cells visible in the slides are related to aqueous humor outflow. 
A dye that could stay perfused in the tissue during the histological studies would 
help in distinguishing lymphatic vessels from blood vessels during the imaging studies. 
This type of dye would allow for direct comparison of the unknown vessels filled with 
dye in vivo and those highlighted as lymphatics with immunohistochemical staining. 
Also, a quantitative measure of the number of vessels perfused, in both the imaging study 
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and the histology slides, or the actual area of diffuse blue perfusion would help with 
comparisons. Immunohistochemistry staining to see intact lymphatic endothelium versus 
broken lymphatic endothelium would help confirm destruction of the lymphatic vessels 
in the horizontal incision samples. Future studies should use a larger number of animals, 
more than 2 rabbits per type of surgery, in order to verify results. 
In summary, the imaging studies hinted at the involvement of lymphatic networks 
in the aqueous outflow pathway created with the shunt, and suggested that the horizontal 
incision surgery is more destructive to the lymphatic vessels of the conjunctiva. Other 
new surgical techniques have been developed recently, and though they some show 
promise none seem to account for the role of the lymphatics. Various innovative surgical 
approaches are talked about next. 
55 
5. SURGICAL GLAUCOMA TREATMENT 
5.1. Introduction 
In some patients, pharmaceutical treatment of glaucoma does not reduce the IOP 
enough to prevent vision loss. Additionally, glaucoma medications are not tolerated by 
some patients because of their side effects, or are an unrealistic option depending on the 
patient's social and economic situation [Dietlein]. When drug therapy fails, surgery is 
another option for patients suffering from glaucoma. Currently, in the United States, 
surgery is usually only considered when necessary because of the many complications 
that can arise. The risk of complete blindness in the first year after surgery is very low, 
but 20% to 30% of patients who undergo surgery experience loss of central visual acuity 
due to cataracts, macular edema, or retinal wrinkling. These complications should be 
addressed if surgery is used as the primary treatment. There are many different types of 
surgery, but they fall into two main categories: conventional and laser surgery. The 
surgical option recommended for a patient varies depending on the type of glaucoma they 
have. In this section, the frequently performed trabeculectomy along with some newer 
surgical techniques are introduced. Though some of these current methods have decent 
success rates, they usually destroy the lymphatic channels that could be essential in 
aqueous outflow following surgery. 
5.2. Trabeculectomy 
The most common type of surgery performed for the treatment of glaucoma is a 
trabeculectomy. During a trabeculectomy a small section of the trabecular meshwork is 
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removed in order to create an opening to drain aqueous humor [Watson, MedicineNet]. 
"Direct modification of the outflow pathway surgically is justified by the hypothesis that 
the majority of outflow obstruction in primary open-angle glaucoma (POAG) lies in the 
juxtacanalicular trabecular meshwork (TM) or inner wall of Schlemm's canal (SC)" 
[Francis 2006]. The new surgically created outflow pathway opens into a pocket in the 
subconjunctival space called a filtering bleb. Collector vessels are thought to transport 
aqueous humor out of the bleb and into systemic circulation. The bleb is necessary to 
prevent the dangerously low IOP that can result from direct contact between the inside of 
the eye and atmosphere. Blebs are extremely important in a trabeculectomy, along with 
other types of glaucoma drainage surgery, and the state they are in can greatly influence 
the success or failure of the drainage surgery. In general, however, a bleb-independent 
surgery would be preferred in order to avoid issues of late bleb failure and bleb infection 
[Peckar]. 
"Trabeculectomy is still the most effective !OP-lowering procedure performed 
today but continues to have the highest serious complication rates," leading to the 
continual search for alternative surgical procedures [Mosaed]. One particular study 
showed that a trabeculectomy has a success rate (IOP of less than 21 mm Hg, IOP 20% 
below baseline in two consecutive visits, and no additional surgery necessary) of 86% 
one year following surgery [Mosaed]. When compared to other surgical methods, a 
trabeculectomy is more effective in lowering IOP. After surgery, patients have an 
average IOP of 12 mm Hg, which is a lower pressure than is typically obtained by using 
other procedures. 
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Despite effectively lowering IOP, many complications frequently occur following 
a trabeculectomy. These include "hypotony, bleb leaks, late blebitis, accelerated cataract 
progression, choroidal effusions and hemorrhage, and prolonged or permanent visual 
impairment from hypotony maculopathy" [Mosaed]. The postoperative complications 
from the surgery, including overfiltration and hypotony, are mainly due to the sudden 
exposure and resulting decompression of the anterior chamber [Lachkar]. 
Antifibrotic agents such as mitomycin C or 5-Fluorouracil are commonly used to 
prevent fibrosis and scarring, which can obstruct the newly created outflow pathway 
following surgery [Johnson 2001, Dietlein]. Without the use of antifibrotic agents the 
trabeculectomy procedure has relatively high short-term failure rates [Mosaed]. 
However, the antifibrotic agents also increase the number of complications that a patient 
experiences and can be the cause of things such as corneal erosion, corneal ulceration, 
conjunctiva! wound leaks, or thin avascular blebs. During the surgery, several 
complications can also occur, including tearing of the conjunctiva! flap, hemorrhage, lens 
injury, vitreous loss, stripping of the descemet's membrane, tearing of the scleral flap, 
and bleeding from the episcleral layer [Nutan]. Due to these severe complications, safer 
surgical techniques have been and continue to be explored for use in treating glaucoma. 
5.3. Surgical Approaches and Other Conventional Glaucoma Surgeries 
There are two different approaches to a trabeculectomy, along with other types of 
glaucoma surgery: ab interno (from the inside) and ab externo (from the outside). The ab 
externo approach is considered to be non-penetrating because the surgeon does not enter 
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or penetrate the anterior chamber. There are conflicting opinions on whether or not non-
penetrating surgeries should be considered before penetrating surgeries, but they do have 
the "advantage of minimizing the risk of postoperative complications related to 
hypotony" [Lachkar]. 
A trabeculectomy is considered to be a partial thickness filtering surgery, which is 
also sometimes referred to as a guarded, protected, or subscleral filtering procedure. 
During a guarded filtering procedure the filtering sclerostomy, or surgical perforation of 
the sclera, is protected by partially closing the scleral flap. In contrast, no guard covers 
the external surface of the sclerostomy in a full thickness procedure. The reduction in 
IOP is comparable in both partial and full thickness surgeries, but the partial thickness 
procedures do not have as many complications related to lower pressures due to the 
presence of the scleral flap [Watkins]. Full thickness procedures are generally avoided 
due to their severe complications. Two different types of conjunctiva! flaps can be used 
to cover the incision in the sclera, with the limbus based conjunctiva! flap being preferred 
over the fomix based flap because it creates a more water tight seal [Nutan]. 
Several other types of glaucoma drainage surgery include trabeculotomy, 
goniotomy, a few different full thickness procedures, iridotomy, and iridectomy. In 
addition, several laser surgeries can be used in the treatment of glaucoma. Laser 
trabeculoplasty and laser cyclophotocoagulation are the main laser treatments for primary 
open angle glaucoma. Though laser techniques are not typically as effective as 
conventional surgery in lowering IOP they have fewer complications. Other conventional 
surgical techniques and laser surgeries are discussed in more detail in Appendix C. 
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5.4. Nonpenetrating Glaucoma Surgeries and Canaloplasty 
Nonpenetrating glaucoma surgeries have recently been utilized because they 
avoid the severe hypotony that can result from entrance into the anterior chamber. There 
are three main types of nonpenetrating surgical procedures used for the treatment of 
glaucoma, all of which are guarded procedures. The first type of nonpenetrating surgery 
is a deep sclerectomy, the second is an external trabeculectomy, and the third is a 
viscocanalostomy [Johnson 2001]. Oftentimes the deep sclerectomy is combined with an 
ab externo trabeculectomy. During a deep sclerectomy a portion of the sclera and cornea 
near to the trabecular meshwork is removed as in a trabeculectomy, but Descemet's 
membrane is left intact and Schlemm' s canal is unroofed. "In deep sclerectomy the 
removal of both deep scleral flap and corneal stroma behind the anterior trabeculum and 
the Descemet membrane allows the aqueous humor to leave the anterior chamber through 
the intact trabeculodescemetic membrane" [Lachkar]. The inner wall of Schlemm' s canal 
and the adjacent layers of the trabecular meshwork are removed during an external 
trabeculectomy. The viscocanalostomy procedure is similar to a deep sclerectomy, 
except a viscoelastic substance is injected into the surgically opened ostia, or ends, of 
Schlemm's canal [Peckar]. In theory, the viscoelastic substance expands certain areas of 
Schlemm's canal and the aqueous collector channels to increase outflow. 
Comparison between nonpenetrating and penetrating procedures is difficult 
because of surgical variations. Several previously reported results show that 
nonpenetrating deep sclerectomy with external trabeculectomy gives a reduction in IOP 
comparable to a conventional trabeculectomy, but with less complications [Lachkar]. 
One study showed the success rate (IOP less than 21 mm Hg and no glaucoma 
medication necessary) at 18 months was 80% in the deep sclerectomy with external 
trabeculectomy group but 88% in the conventional trabeculectomy group. In this study 
goniopuncture, sometimes used after a deep sclerectomy with external trabeculectomy, 
was used as a follow-up procedure in a third of the patients. A different study found a 
statistically significant difference between the postoperative IOPs of patients who 
underwent a deep sclerectomy with external trabeculectomy (20.9 mm Hg) and patients 
who underwent a conventional trabeculectomy (17.3 mm Hg) [Chiselita]. 
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Canaloplasty is also a novel nonpenetrating surgical procedure similar to a 
viscocanalostomy that can be used for glaucoma therapy. During a canaloplasty, a 
microcatheter is inserted into Schlemm's canal (see Figure 2.1) and then a viscoelastic 
substance is continually injected through the catheter as it is slowly removed from the 
incision [Peckar]. Canaloplasty and viscocanalostomy are newer procedures that have 
shown some promising results in clinical trials, giving similar reductions in IOP to 
trabeculectomy with low rates ofhypotony and other complications. One study showed 
that viscocanalostomy had an overall success rate (IOP reduction less than 30% but IOP 
less than or equal to 20 mm Hg) of 88% at 1 year, 90% at 2 years, and 88% at 3 years 
[Sunarevic-Megevand]. 
Another randomized trial that compared viscocanalostomy and trabeculectomy a 
year following surgery showed a comparable reduction in IOP in between the 
viscocanalostomy group (24.6 mm Hg preoperative to 14.0 mm Hg postoperative) and 
trabeculectomy group (22.3 mm Hg preoperative to 13.3 postoperative) [Carassa]. One 
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surgeon said 85% of his viscocanalostomy patients and 95% of his canaloplasty patients 
had an IOP less than 21 mm Hg following surgery [Peckar]. Overall , the nonpenetrating 
procedures oftentimes give a similar reduction in IOP with fewer complications when 
compared to a trabeculectomy. Therefore, I believe that nonpenetrating procedures, in 
particular the seemingly successful canaloplasty procedure, should be considered as a 
replacement for conventional surgical methods. 
Figure 5.1 Image showing the insertion of a catheter during a canaloplasty [New 
Glaucoma Treatments] 
5.5. Trabectome™ 
A tool called a Trabectome TM is currently under investigation to evaluate its 
safety and efficacy for use during drainage surgery. The Trabectome is a 
microelectrocautery device that was developed in 2004 for the treatment of glaucoma 
[Mosaed]. An ab interno approach is used with this surgical instrument in order to ablate 
a portion of the trabecular mesh work and inner wall of Schlemm' s canal, opening up a 
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portion of the drainage channel (see Figure 2.2). The Trabectome has been shown to 
have the ability to disrupt the desired area of the trabecular meshwork and Schlemm' s 
canal without damaging surrounding tissue [Francis 2006]. With the use of the 
Trabectome, the conjunctiva, sclera, and Tenon capsule are preserved, allowing for 
additional drainage surgery if necessary [Liu]. Transient hyphemia, or bleeding into the 
anterior chamber, is the most common complication seen when the Trabectome is used, 
with no patients reporting permanent visual impairment, choroidal effusions, or infections 
[Francis 2006]. In addition, there is no bleb formation with this process, so there is no 
risk ofbleb infection, bleb leak, saucer shaped excavations at the edge of the cornea, or 
inflammation in the intraocular cavities. 
A success rate (defined as no additional glaucoma surgery) of 89.6% has been 
shown for procedures where the Trabectome is used, with the IOP typically stabilizing in 
the mid-teens through 5 years of follow-up in patients where the procedure is successful. 
Even though there is a greater reduction in IOP following a traditional trabeculectomy 
(12.7 mm Hg postoperative for trabeculectomy versus 16.1 mm Hg postoperative with 
the Trabectome ), there are less complications with the use of a Trabectome, making it a 
promising new tool for glaucoma therapy [Francis 2006, Liu]. 
Figure 5.2 Image showing how the Trabectome TM surgical tool is used to remove 
portions from the trabecular meshwork during glaucoma drainage surgery [Stamper 
2011] 
5.6. Fugo Blade and Excimer Laser Trabeculotomy 
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Other new types of surgical therapy include Fugo blade transciliary filtration and 
Excimer laser trabeculotomy (EL T). "The Fugo blade is an electrosurgical device that 
produces noncauterizing hemostasis and precise tissue cutting while minimally affecting 
the adjacent tissue and sterilizing the wall of the incision" [Francis 2011]. Transciliary 
filtration with a Fugo blade involves creating an opening from the posterior chamber of 
the eye to the subconjunctival space in order to filter out aqueous humor. Antifibrotic 
agents are not necessary following the transciliary filtration procedure, and it is a quick, 
low cost option. However, there is bleb formation and the risk of hypotony after surgery. 
A retrospective case study on Fugo blade transciliary filtration showed that 85% of 
patients had an IOP of less than 21 mm Hg without medications or the need for a repeat 
surgery. In another study, 76.6% of patients had an IOP less than 30 mm Hg with no 
need for supplementary drugs after a Fugo blade transciliary filtration [Dow]. 
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A goniotomy, or the creation of an opening through the trabecular meshwork 
directly to Schlemm's canal, can also be completed ab intemo with a Fugo blade. 
Performing a goniotomy with a Fugo blade has the advantages of no bleb formation, low 
risk ofhypotony, and no destruction of the conjunctiva [Singh 2006]. Disadvantages of 
the procedure include blockage of the new opening through fibrosis and difficult control 
of ablation depth. A small study showed that 87 .5% of patients had an IOP less than 21 
mm Hg 6 months after a Fugo blade goniotomy. More experiments need to be done to 
study the effectiveness and safety of these new Fugo blade techniques, but the few 
published studies show that they have a lot of potential. 
Excimer laser trabeculotomy (EL T) uses a xenon chloride excimer laser 
connected to a fiberoptic probe to make holes in the trabecular meshwork and inner wall 
of Schlemm's canal. Unlike other laser surgeries, the ablation during an ELT is more 
controlled and the trabecular meshwork does not sustain heat damage. However, the 
smaller openings created during an EL T are more prone to closure and it is more invasive 
than other laser surgeries. A small prospective study showed an IOP decrease of 20% 
with no supplementary medication necessary in 54% of patients [Babighian]. Since bleb-
related issues, fibrosis, or channel blockage can cause failure after conventional surgeries, 
drainage devices and other approaches should be considered to create a permanent 
outflow pathway. 
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6. IMAGING METHODS TO VIEW AQUEOUS OUTFLOW 
Many of the surgical techniques previously discussed do not protect lymphatic 
outflow in the eye, so a new surgical approach was explored in a rabbit study. Though 
trypan blue was the chosen imaging method in this study given our resources and other 
practical constraints, other imaging methods to visualize lymphatic vessels may be more 
useful in developing a surgical technique to preserve the lymphatic channels. 
6.1. Advantages to Effective Imaging of Aqueous Outflow 
"Developments in optical imaging techniques designed for the eye, such as 
scanning laser polarimetry, confocal scanning laser ophthalmoscopy, and optical 
coherence tomography, have taken advantage of the naturally clear optical pathway that 
provides access to the internal features of the eye" but "can acquire only limited 
information beyond the level of the retinal pigment epithelium" [Townsend]. 
Discovering a way to clearly and accurately imaging the aqueous outflow pathway would 
be extremely valuable. Methods to visualize lymphatic vessels near the eye have recently 
been introduced because lymphatics are now thought to have a large contribution to 
aqueous humor outflow, particularly when the eye is in a diseased or inflamed state [Yu]. 
Imaging modalities such as contrast-enhanced ultrasound have been successfully used for 
imaging lymphatics [Goldberg]. More recently, photoacoustic imaging has been used for 
viewing the vasculature around the eye [Li]. 
Previous experiments provide good evidence that imaging the outflow pathways 
in the eye with greater accuracy and fidelity is possible. It is extremely important to be 
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able to visualize the outflow pathways in the eye both before and after conventional 
surgery, laser surgery, or implantation of a glaucoma shunt in order to improve upon the 
technique or device. Also, a great deal currently not understood about the outflow 
pathways in the eye could be elucidated with further imaging studies. There are many 
different imaging methods that have the potential to accurately image the aqueous humor 
outflow pathways in the eye. All of these imaging methods need to be compared to 
ensure fidelity in imaging both the lymphatic channels and vasculature near the eye. 
6.2. Fluorescein Imaging 
Fluorescein is a substance that can be used as a tracer in the imaging of the 
lymphatic networks. Fluorescein has an excitation wavelength of 465-490 nm, and the 
camera should have a 520-530 nm barrier filter to properly capture images. Typically, 
fluorescein is used in fluorescein angiography, which is "an important tool for 
ophthalmologists in understanding, diagnosis, and treatment of retinal disorders" 
[Bennett]. When injected into systemic circulation it can be used to visualize the 
vasculature. However, studies have also shown that fluorescein can be used to trace and 
study aqueous humor outflow (see Figure 6.1) [Yu]. Though using a pre-placed contrast 
agent to visualize and protect the lymphatics during surgery would be beneficial, tests 
have shown that several of the dyes commonly used in the eye, such as indocyanine green 
and trypan blue, are toxic to retinal cells [Kodjikian]. Therefore, care must be taken 
when using these contrast agents in the eye, and less toxic alternatives should be 
considered. 
Figure 6.1 Fluorescein imaging of the aqueous humor outflow pathway in the eye, 
following injection into the anterior chamber of a rabbit eye [Yu] 
6.3. Preliminary Imaging Study with Fluorescein 
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Imaging studies were completed to detennine the most effective way to visualize 
aqueous humor outflow. The studies were performed on enucleated eyes with IACUC 
approval, under bioproducts protocol #10-236. Porcine, bovine, and ovine eyes were 
procured from the University of Arizona meat science lab. 
Prior to doing any perfusion studies, several images were taken with the Zeiss slit 
lamp microscope in order to visualize the blood vessels. With 16x and 40x 
magnification, the vessels in the enucleated eyes were clearly visible. The amount of 
light was adjusted to allow for more clear images of the vessels. 
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Figure 6.2 Image showing scleral blood vessels in an ovine eye 
Fluorescein was used in the attempt to visualize the aqueous humor outflow in the 
eye. In order to mix the fluorescein, sodium ophthalmic strips (purchased from Bio Glo, 
1 mg strips) were placed in 2-3 mL of balanced salt solution (purchased from Akorn) to 
make a solution of sufficient concentration to be clearly visible. Images were taken from 
a Zeiss slit lamp microscope with up to 40x magnification on either a standard Canon 
rebel digital camera attached to the slit lamp microscope, or a 10.1 megapixel Nikon 
coolpix digital camera through the oculars. At times, a cobalt filter was used in order to 
filter out certain wavelengths of light and selectively excite fluorescein. The cobalt filter 
allowed for better visualization of the fluorescein alone. 
Several different methods were used in order to view perfusion in the eye. First, 
the perfusion of a one-time injection of dye directly into the anterior chamber was 
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examined as a preliminary experiment. Then, the diffusion of the dye from a 
subconjunctival bleb was observed. Lastly, the continuous perfusion of dye into both the 
anterior chamber and subconjunctival bleb was viewed at a constant pressure. The setup 
for the continuous perfusion study was a syringe connected to a tube with a 23 gauge 
needle at the end. The 23 gauge needle was then inserted into either the anterior chamber 
or subconjunctival space of the eye (see Figure 6.5 for the experimental setup). The 
hydrostatic pressure of the dye being injected into the enucleated eyes was controlled by 
adjusting the height of the syringe to the desired value of pressure head. The pressure 
was typically set close to physiological pressure, around 20 mm Hg. 
Figure 6.3 Setup of the continuous perfusion pressure studies 
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The fluorescein was visible in the anterior chamber of many of the samples after 
injection, but the dye was not typically visible outside of the anterior chamber or the 
subconjunctival blebs (Figures 6.4 and 6.5). The subconjunctival blebs became larger 
over time, showing that the fluorescein did diffuse through the subconjunctival space 
(Figure 6.6). Neither the aqueous collector blood vessels nor potential lymphatic 
collector vessels were highlighted by the fluorescein dye in the eyes that were tested. 
Even the addition of the cobalt filter did not seem to assist with visualization of the dye 
flowing through the vessels. In only one case was there a blood vessel visibly filled with 
fluorescein (Figure 6.10 to Figure 6.12). 
A potential explanation for not seeing the fluorescein is that the concentration of 
the fluorescein dye, though enough to be visible to the dye prior to injection, may not 
have been high enough to be visible through tissue. Another possible explanation for 
failure in some of the samples is that removal of the eyes from the animals could impair 
the function of the vessels and outflow network, particularly the lymphatic vessels, to the 
point where perfusion outside of the anterior chamber does not occur. One thing that 
may have helped with the fluorescein imaging is to have a filter on the camera itself to 
selectively view the wavelength of light that fluorescein gives off when excited by light 
from the cobalt filter. Fluorescein images are shown from Figure 6.4 to Figure 6.12. 
Figure 6.4 Image showing fluorescein dye in the anterior chamber and a conjunctival 
bleb filled with fluorescein dye in a bovine eye ( 1 Ox magnification) 
Figure 6.5 Image showing fluorescein dye in the anterior chamber and a conjunctiva! 
bleb filled with fluorescein dye in a bovine eye ( l 6x magnification) 
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Figure 6.6 Image showing the diffusion of a subconjunctival bleb of fluorescein through 
the tissue as it grows in size over time from the top picture to the bottom picture in a 
bovine eye (16x magnification) 
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Figure 6.7 Image showing a subconjunctival bleb of fluorescein in a porcine eye (25x 
magnification) 
Figure 6.8 Image showing a subconjunctival bleb of fluorescein in a porcine eye (same 
as in Figure 6. 7), under a cobalt filter ( 6x magnification) 
74 
Figure 6.9 Image showing a subconjunctival bleb of fluorescein (same as in Figure 6. 7) 
under a cobalt filter in a porcine eye (25x magnification) 
Figure 6.10 Image of a blood vessel with potential fluorescein perfusion, near a 
subconjunctival bleb of fluorescein in a porcine eye (25x magnification) 
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Figure 6.11 Image of a blood vessel with potential fluorescein perfusion, near a 
subconjunctival bleb of fluorescein (same as in Figure 6.10) and under a cobalt filter in a 
porcine eye (6x magnification) 
Figure 6.12 Image of a blood vessel with potential fluorescein perfusion, near a 
subconjunctival bleb of fluorescein (same as in Figure 6.10) and under a cobalt filter in a 
porcine eye (25x magnification) 
6.4. Trypan Blue Imaging 
Trypan blue is a vital dye, and it is commonly used in microscopy to assess the 
viability of different cells. Though trypan blue is most commonly used in ophthalmology 
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to view the lens capsule during cataract surgery, it has also been shown to be effective in 
visualizing the lymphatic networks in the eye [Jacobs]. Trypan blue can be injected into 
the subconjunctival tissue to create interstitial tissue fluid, which then drains through the 
lymphatics (see Figure 6.13). The subconjunctival pool of trypan blue is observed in 
order to evaluate if it remains stagnant, meaning lack of lymphatic drainage, or if it 
spreads away from the blister, indicating the existence of lymphatic drainage and 
showing the distinct branch-like tributaries [Yu]. Lymph dynamics and principal 
collectors in all four quadrants can be recorded by slit lamp microscopy and digital video 
microscopy. During studies with Fugo blade transciliary filtration, Singh et. al learned 
more about the lymphatic drainage system by using trypan blue. "Using trypan blue 
staining, Dr. Singh was able to visualize the lymphatic drainage system as it carried the 
aqueous away from the ciliary body" [Bethke]. 
Figure 6.13 Trypan blue perfusion into the lymphatic networks of a rabbit eye following 
injection into a subconjunctival bleb [Yu] 
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6.5. Preliminary Imaging Study with Trypan Blue 
In our study, when the fluorescein imaging did not properly show the path of the 
aqueous humor as it left the anterior chamber or a subconjunctival bleb, trypan blue 
(purchased from Sigma-Aldrich) imaging was also tested. The same setup was used in 
the fluorescein study and the trypan blue study. A benefit of using trypan blue over 
fluorescein is that it can be visualized without the use of any filters. The trypan blue 
imaging much more clearly showed the aqueous humor outflow, especially when there 
was continuous perfusion of the dye into either the anterior chamber or a subconjunctival 
bleb at a known pressure (see Figures 6.14 to 6.17). Several of the vessels visible with 
the perfusion of trypan blue resembled lymphatics when compared to pictures in previous 
studies by Yu et. al and Singh et. al (see Figure 6.15). The vessels showed possible valve 
structures and were distinct from nearby blood vessels, both things characteristic of 
lymphatic vessels (see Figures 6.14 to 6.16). Trypan blue images are shown from Figure 
6.14 to Figure 6.18. 
Figure 6.14 Image showing trypan blue perfusion from a subconjunctival bleb to 
potential lymphatics, near to a blood vessel in an ovine eye ( 40x magnification) 
Possible lymphatics 
I 
Figure 6.15 Image of potential lymphatics perfused with trypan blue in an ovine eye 
( 40x magnification) compared with an image of lymphatics from Yu et. al 
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Figure 6.16 Image showing trypan blue perfusion from the anterior chamber to potential 
lymphatics, near to blood vessels in an ovine eye ( 40x magnification) 
Figure 6.17 Image showing trypan blue perfusion from the anterior chamber to potential 
lymphatics in an ovine eye ( 40x magnification) 
A study performed with the constant injection of trypan blue at different 
hydrostatic pressures showed that perfusion from the anterior chamber into the nearby 
vessels occurs at around 15 mm Hg, which is close to the physiological pressure in the 
eye (Figure 6.18). No perfusion was seen into vessels near to the anterior chamber at 5 
mm Hg and l O mm Hg. However, perfusion began at 15 mm Hg, and dye was seen in 
even more vessels as the pressure was raised to 20 mm Hg. 
5/10 mm Hg 15 mm Hg 20 mm Hg 
Figure 6.18 Image showing the perfusion of trypan at different hydrostatic pressure 
values, from 5 mm Hg to 20 mm Hg, in an ovine eye 
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Overall, the imaging studies showed that trypan blue is a more convenient and 
effective method of imaging aqueous humor outflow when compared with fluorescein 
imaging. Vessels that resembled lymphatic channels were highlighted in enucleated eyes 
using trypan blue. In addition, perfusion performed at different pressures showed 
evidence that the trypan blue did not fill the vessels until the hydrostatic pressure was 15 
mm Hg. In order to confirm that the lymphatics can be viewed using trypan blue, more 
in vivo studies should also be completed. 
6. 6. Two-Photon Microscopy 
Fluorescent dyes could also be used as contrast agents for in vivo two-photon 
fluorescent light microscopy [So]. "Two-photon microscopy is a nonlinear imaging 
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technology with subcellular resolution capabilities that has been previously used to image 
ocular tissues without the need for fixation" [Johnson 2011]. There are many different 
fluorescent proteins that could be used for imaging, including green fluorescent protein, 
yellow fluorescent protein, and cyan fluorescent protein. In order to prevent excessive 
diffusion outside of the lymphatic networks in the eye, the fluorescent molecules could 
potentially be coupled to larger molecules such as dextran. Some molecules in the body 
are naturally fluorescent, such as NADH and NADPH, and therefore different cellular 
processes can be monitored using two-photon excitation autofluorescence microscopy 
[Imanishi]. 
Second harmonic generation is another two-photon technique that occurs when 
the structure being observed scatters the two infrared photons instead of absorbing them, 
and the photons coalesce into one higher energy photon. Two-photon microscopy has 
been used to study the action of the cells in the retina and the structure of the cornea, and 
it has aided understanding of these tissues. A limitation of two-photon microscopy is its 
depth of penetration. One study looking at the diffusion of a tracer through the sclera 
showed that imaging with two-photon microscopy was possible to a depth of 340 
micrometers, the average thickness of the human sclera [Kek]. Another recent study 
attempted to image the aqueous outflow pathways in a mouse eye (Figure 6.19). This 
study showed that "two-photon microscopy may be used for noninvasively imaging the 
conventional aqueous outflow pathway in mouse models of glaucoma," with expected 
future work on live animals [Johnson 2011]. Two-photon microscopy is a fairly new 
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imaging technique that has potential for imaging the aqueous humor outflow pathway in 
vivo, though it probably lacks the ability to distinguish specific vasculature. 
Figure 6.19 Image showing a comparison of auto-fluorescent two-photon microscopy 
and histology slides [Johnson 2011] 
6. 7. Ultrasound 
Sonographic imaging could be used to visualize the vascular and lymphatic 
networks in the eye in vivo. In previous studies, lymphatic channels and sentinel lymph 
nodes have been successfully imaged using microbubble contrast agents, despite their 
size limitations (Figure 6.20, top) [Goldberg, Bloch]. Various contrast agents need to be 
utilized in order to gauge whether or not they can effectively image the lymphatics near 
the eye. These ultrasound contrast agents could be monitored for uptake into the 
lymphatic channels as described previously using fundamental 2-D gray scale and color 
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flow imaging (CFI) as well as gray scale pulse inversion hannonic imaging (GSPIHI) and 
multiplanar 3-D sonography [Goldberg). 
Sonazoid, Definity, and Optison are three potential microbubble contrast agents 
that could be tested for efficacy in highlighting the lymphatic and vascular pathways in 
the eye. In addition, the blood flow near the eye can be viewed using doppler color flow 
imaging. One study looked at using volumetric color doppler imaging in order to image 
ocular blood flow in glaucoma patients [Zeitz]. The study showed that regular color 
doppler imaging gave very reproducible results for blood velocity in the opthalmic artery 
and central retinal artery, while volumetric blood flow was not as accurate and needs to 
be optimized before its used in a clinical setting (Figure 6.20, bottom). 
Figure 6.20 Image showing the highlighting of lymphatic vessels using an ultrasound 
contrast agent (top) and the flow of blood in ocular blood vessels using color doppler 
imaging (bottom) [Goldberg, Zeitz] 
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6.8. Magnetic Resonance Imaging (MRI) 
MRis are routinely done on the eye to look for things such as tumors, infections, 
ocular neuropathy, or swelling of the optic nerve [Berkowitz]. MRI is an imaging 
technique that uses varying magnetic fields to distinguish between different types of 
tissue. One study attempted to use diffusion MRI to distinguish between different ocular 
conditions [Xu]. Though there are difficulties involved with finding the MRI sequence 
that gives the best contrast and most accurate results to make a diagnosis, researchers are 
steadily working toward methods that can elucidate different disease states in the optic 
nerve. A recent study displayed a novel method for diffusion tensor imaging that was 
able to distinguish patients that were suffering from glaucoma with 94% accuracy 
[Engelhom]. Several other studies proved that MRI could be useful for the diagnosis of 
glaucoma and distinguish between the patients with glaucoma and the healthy controls 
using parameters such as optic nerve diameter and optic chiasm [Townsend]. 
MRI can also be used after the implantation of a glaucoma drainage device to 
visualize its position and function. A study looking at glaucoma shunts showed that 
"magnetic resonance imaging provides insights into the mechanism of aqueous outflow 
and causes of failure of shunts" [Detorakis]. Functional MRI ( tMRI) is another form of 
MRI that has been used to map the activity of the retina. In studies with glaucoma tMRI 
has demonstrated the ability to view "alterations involving the human visual cortex that 
are consistent with clinically documented loss of visual function" [Garaci]. 
Another study attempted to visualize ocular blood flow in a rat model of 
glaucoma using Gd-DTPA contrast-enhanced MRI (Figure 6.21) [Chan]. After systemic 
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administration of Gd-DTP A Chan et. al noticed an increased signal intensity in the 
vitreous compartment of the glaucomatous eye but not in vitreous compartment of the 
normal eye, showing that increased permeability of the blood-aqueous or aqueous-
vitreous barrier is a potential step in the progression to glaucoma. Overall, this study 
showed that imaging of aqueous humor is possible given a contrast agent such as Gd-
DTP A, but more experiments need to be completed to assess the possibility of using MRI 
to visualize outflow through the trabecular meshwork when contrast agent is injected 
directly into the anterior chamber. An issue with using MRI to properly diagnose 
glaucoma is that it is not very cost effective compared to the traditional methods for 
diagnosis [Townsend]. In addition, MRI may not be practical for visualizing aqueous 
humor outflow in real time due to the long scanning periods. 
Figure 6.21 MRI image taken at different time points after the injection of Gd-DTP A 
contrast agent in order to visualize ocular blood flow [Chan] 
6.9. Computed Tomography (CT) 
Computed tomography (CT) is another imaging method that could potentially be 
used to image aqueous humor outflow. CT scans compile a series ofx-rays to form a 3D 
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image of the anatomy, with different tissue types being separated by how much they 
attenuate the x-rays before they are detected. One study that looked at aqueous humor 
outflow with CT showed that "3D micro-CT can be used effectively for the non-invasive 
examination of the trabecular mesh work, Schlemm' s canal, collector channels and 
intrascleral vasculature that comprise the distal outflow pathway" (Figure 6.22) [Hann]. 
During the study several CT contrast agents, including osmium, were also explored. The 
experiment was completed in enucleated eyes, so the efficacy of this imaging method 
needs to be tested in vivo to prove its usefulness in imaging aqueous humor outflow 
though the scanning times may prevent real time imaging of aqueous outflow. 
Figure 6.22 CT image of the angle of the eye showing the various structures of the 
aqueous humor outflow pathway, including vessels and collector channels (CC) [Hann] 
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6.10. Photoacoustic Imaging and Optical Coherence Tomography 
Photoacoustic imaging has recently been used in conjunction with optical 
coherence tomography to image the microvasculature in the eye [Li]. Photoacoustic 
imaging involves analyzing the sound waves generated when tissue is heated with a laser, 
which vary depending on the tissue type. A contrast agent is not necessary to view 
vasculature due to the optical properties of blood, but it could be useful in distinguishing 
between the vasculature and lymphatic vessels near the eye. Photoacoustic imaging an 
extremely promising option for visualizing aqueous humor outflow in the eye, and it has 
already been used in conjunction with optical coherence tomography to image the blood 
vessels of the eye (Figure 6.23) [Li]. The photoacoustic images clearly show the ocular 
blood vessels with remarkable precision, with the overlaid OCT images providing 
anatomical information. A contrast agent could be injected into the anterior chamber and 
its outflow could be monitored real time with this imaging modality. In addition, the 
vessels highlighted with the photoacoustic contrast agent could easily be compared with 
the vasculature visible in the photoacoustic images and the anatomical information seen 
in the OCT images. 
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Figure 6.23 Photoacoustic imaging (d and g) combined with OCT imaging (f and i) to 
visualize both the vasculature and the anatomical structures simultaneously [Li] 
Optical coherence tomography (OCT) is another imaging modality that is 
commonly used to image the eye [Bennett]. The principles behind optical coherence 
tomography involve imaging the reflection of light from tissue, and since it is based on 
light it has a very good resolution but not good tissue depth. It can "provide direct cross-
sectional images of the macula, retinal nerve fibre layer and optic nerve for objective 
measurement and clinical evaluation ofretinal diseases and glaucoma" [Bennett]. Ocular 
structures can be very clearly viewed using OCT (Figure 6.24, left), but it is an 
anatomical imaging modality and would most likely not be practical for following the 
aqueous humor itself. OCT has recently been used to view the aqueous humor pathways 
in situ. In a recent study, spectral-domain OCT was successfully used to view the 
aqueous humor pathway, including the aqueous collector veins (Figure 6.24, right) . 
"Schlemm's canal, collector channels, the deep and intrascleral venous plexus, and 
episcleral veins were observed throughout the limbus while the aqueous veins could be 
observed extending into the episcleral veins" [Kagemann]. 
Overall, I strongly suspect that the combination of photoacoustic and OCT 
imaging has the most promise for accurately and effectively visualizing the lymphatic 
networks of the eye in vivo. The photoacoustic imaging offers amazing precision in 
viewing blood vessels, while the OCT offers a great way to view the anatomical 
structures in the eye. Photoacoustic imaging could easily be adapted to view lymphatic 
vessels with great exactitude. Also, ultrasound equipment is already available in many 
hospitals and OCT is available for use in ophthalmology, so these imaging modalities 
could be used in the clinic prior to glaucoma drainage surgery to visualize and 
subsequently avoid destroying the lymphatic channels. Future experiments should be 
completed to confirm the utility of these imaging methods for visualizing aqueous 
outflow. 
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Figure 6.24 OCT image of the anterior chamber, showing the anatomical structures 





There are many different medications used in the treatment of glaucoma, but they 
have adverse side effects, poor patient adherence, and high costs. When pharmaceutical 
agents do not sufficiently lower IOP, surgery should be considered. There are a great 
deal of adverse side effects associated with glaucoma drainage surgery, and many times 
patients still need to be on pharmaceutical therapy following surgery. Despite these 
downfalls to glaucoma surgery, an improved surgical treatment as first-line therapy 
would be extremely beneficial to those suffering from glaucoma who do not have access 
to the conventional drug treatments. Though traditional glaucoma surgery is still used 
more frequently than glaucoma shunts, there is a growing trend towards the use of 
drainage devices. One glaucoma drainage device that shows a lot of promise is the 
porous e-PTFE device. In preliminary studies the e-PTFE shunt was shown to allow a 
high enough flow rate to properly lower IOP, even under increased protein 
concentrations. The e-PTFE implant could even be further modified to optimize its flow 
properties by changing the pore size, altering the geometry, or attaching molecules to the 
surface (i.e. antifibrotics). 
Recent experiments have shown that lymphatics are essential in aqueous humor 
outflow following glaucoma drainage surgery. The in vivo rabbit experiment showed 
more evidence of the involvement of lymphatic vessels in aqueous humor outflow 
following surgery, though more specific histological staining would help validate the 
presence of lymphatic channels. Further experiments need to be done in order to 
conclusively elucidate the difference between surgery with a vertical incision and surgery 
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with a horizontal incision. The original experiments discussed in this paper describe 
several favorable properties of the e-PTFE glaucoma shunt along with the perfusion of 
dye through lymphatic and blood vessels in the eye. Overall, previous studies along with 
the studies conducted in this paper support the hypothesis that e-PTFE and the surgical 
approach should specifically aim to preserve conjunctiva! and peribulbar lymphatic and 
blood vessels as potential conduits for the egress of fluid released by the glaucoma 
drainage device. 
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8. FUTURE WORK 
In future work, researchers could look into inducing the growth of more vascular 
and lymphatic vessels near the glaucoma drainage devices in order to improve the 
outflow pathways of the eye. Various ways to manipulate blood vessel and lymphatic 
growth near the cornea using factors such as VEGF, VEGF-C and bFGF have been 
explored in previous experiments [Oh, Chung]. Typically, a reservoir will develop that 
inhibits outflow and decreases the effectiveness of the shunt. It is thought that this 
reservoir can create a backpressure that prevents proper aqueous humor outflow. 
Therefore, it is important to look into methods of reducing this reservoir. Promoting 
vascular and lymphatic growth near the promising e-PTFE shunt could assist in the 
reabsorption of fluid, thereby allowing more efficient humor outflow through the device. 
Growth factors such as VEGF-A and bFGF can stimulate angiogenesis. 
Neovascularization and growth factors play an important role in the eye, and anti-VEGF 
factors are used to treat ocular diseases such as age-related macular degeneration. 
VEGF-A is a potent angiogenic factor that encourages angiogenesis by increasing cell 
migration of endothelial cells, proliferation of endothelial cells, matrix metalloproteinase 
activity, anti-apoptotic activity, and alpha-v beta-3 integrin activity while creating blood 
vessel lumen and fenestrations [NIH]. This growth factor is also a vasodilator and can 
increase microvascular permeability. Additionally, it has recently been shown that 
transgenic overexpression ofVEGF-A in mice can also promote lymphatic growth near a 
wound site [Hong]. Another important angiogenic ligand is bFGF. The bFGF mediates 
the formation of new blood vessels once it is activated by the degradation of heparin 
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sulfate in the extracellular matrix during wound healing. In general, bFGF promotes new 
blood vessel growth by increasing mitogenicity of cells, enhancing precursor endothelial 
(angioblast) cell growth, and promoting the migration of endothelial cells [Skjerpen]. 
Also, through previous studies bFGF has been shown to encourage the growth of 
lymphatic vasculature in the cornea [Chung]. 
Lymphatic vessel growth is also expected to aid in the drainage of aqueous humor 
from the e-PTFE glaucoma shunt. In the eye, tissue resembling lymphatic tissue in both 
structure and function is present in the inner wall of the Schlemm' s canal, which is the 
path that the aqueous humor travels before entering systemic circulation [Ramos]. 
Lymphatic tissue naturally grows in parallel to the blood vasculature. 
Lymphangiogenesis is thought to occur when lymphatic sacs develop near veins, as 
stated by the centrifugal sprouting theory. Therefore, the intraocular pressure (IOP) is 
controlled by the presence of both blood and lymphatic vasculature. VEGF-C is a growth 
factor that induces lymphangiogenesis by preferentially binding to the VEGFR-3 
receptor, which is essential in lymphatic system development [NIH]. Angiopoietin 1&2 
are growth factors typically associated with angiogenesis, but they have also been shown 
through experimentation to be extremely important in the formation of lymphatic 
networks [Morisada]. Therefore, both VEGF-C and Angiopoietin 1&2 could be utilized 
as lymphatic growth factors. In conclusion, enhancing vascular and lymphatic growth 
while preserving the lymphatic networks already in place is a promising way of 
improving aqueous outflow from glaucoma drainage devices, of which the e-PTFE 
implant is an exciting new option. 
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A.2. Types of Glaucoma 
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There are several different types of glaucoma. Primary open angle glaucoma is 
the most common form type of glaucoma, affecting two-thirds glaucoma patients 
[Gupta]. The increased IOP in primary open angle glaucoma develops because of 
resistance to aqueous humor outflow through the normal drainage pathways, in particular 
the trabecular meshwork. In another type of glaucoma, nonnal tension glaucoma, the 
IOP is within the normal range, 10-20 mm Hg, but damage to the RGCs still occurs. 
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Possible causes of normal tension glaucoma include "poor blood flow to the optical disk, 
increased susceptibility to disk damage at lower IOP," or low cerebral spinal fluid 
pressure [Gupta, Ren]. The exact causes of normal tension glaucoma are still unknown. 
Primary angle closure glaucoma is yet another form of glaucoma, characterized 
by "contact between the peripheral iris and posterior trabecular meshwork," with no other 
abnormalities in the eye [ Amerasingh]. In angle closure glaucoma, the angle between the 
cornea and the iris essentially closes [GRF]. There are four different mechanisms 
implicated in the development of angle closure glaucoma including pupil-block, anterior 
non-pupil block, lens related and retrolenticular pathways [Amerasingh]. Secondary 
forms of both open angle (pigmentary or pseudoexfoliative) and angle closure glaucoma 
are the result of mechanical or physical blockage of the outflow pathways, or changes in 
its structure due to inflammation, eye injury, cataracts or diabetes. Congenital glaucoma 
occurs in infants when the aqueous humor outflow pathway is not formed properly in the 
womb. Other rare types of glaucoma include neovascular glaucoma and irido corneal 
endothelial syndrome [GRF]. Treatment regimes for glaucoma should account for the 
type that manifests, since different therapies are more effective for specific variations. 
A.3. Prevalence of Glaucoma and Risk Factors 
The distinct forms of glaucoma affect different populations at varying rates, 
which makes it difficult to obtain consistent numbers on the prevalence of the various 
forms of glaucoma. In the United States it is estimated that primary open angle glaucoma 
is the diagnosis in almost 90% of glaucoma cases [GRF]. Normal tension glaucoma is 
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more common in Japan, accounting for an estimated two-thirds of cases there [Gupta]. In 
India and East Asia primary angle closure glaucoma is more common than in other 
regions, affecting roughly half of those patients who have glaucoma in India and causing 
bilateral blindness in an astounding ninety percent of patients in China [Gupta, 
Amerasingh ]. 
There are other risk factors for glaucoma, including family history, age, race, 
gender, diabetes, and high blood pressure [Gupta]. The prevalence of glaucoma increases 
with age, with visual impairment being largely confined to adults over 50. A genetic 
factor is present in some cases of glaucoma, so different genes are being studied for their 
role in the development in glaucoma. In particular, mutations in the myocilin (MYOC) 
trabecular meshwork inducible glucocorticoid response (TIGR) gene cause the onset of 
both juvenile and adult onset primary open angle glaucoma [Huang]. Race is a factor as 
well, with African Americans and Hispanics being roughly 4 times more likely to 
develop glaucoma than any other race [Vetrugno, Kim 2010]. Additionally, women are 
more likely to have chronic angle closure glaucoma and normal tension glaucoma than 
men. People who are far-sighted have shown an increased incidence of glaucoma. 
Angiopathy in Diabetes can lead to the progression of glaucoma, and high blood pressure 
can increase the IOP. 
Appendix 8: Glaucoma Medications 
B.1. Beta Blockers 
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Beta blockers directly decrease aqueous humor production in the ciliary body 
[GRF]. There are several beta blockers currently on the market, including a few 
variations of timolol (i.e. timolol maleate and timolol hemihydrate ), betaxolol, 
metipranolol, pindolol, carteolol, and levobunolol. These medications were first 
introduced in 1979 and have been the first line of therapy for glaucoma since, with 
timolol as the gold standard for glaucoma treatment [Vetrugno]. The usage of beta 
blockers has declined since 1992 from two-thirds of all glaucoma cases to only one-third 
of glaucoma cases, mainly due to their side effects. The price of these drugs is dependent 
on the exact formulation, but they range from costing patients $130 a year (generic 
timolol maleate 0.5%) to $370 a year (betaxolol hydrochloride) [Vold]. They are usually 
applied once or twice a day and the concentration, not the dosing regimen, is varied to 
modify the reduction in IOP. 
Typically beta blockers are both safe and effective, but there can be some 
significant side effects associated with their use. The type and severity of the side effects 
depend on the selectivity of the beta blocker. For example, betaxolol has fewer side 
effects than timolol or levobunolol because it is selective to the beta-1 receptors, but it is 
not as effective in controlling IOP [Vetrugno]. Many patients say they experience 
stinging, burning, red eye, itching, tearing, and loss of feeling in the cornea when 
applying certain beta blockers [Gupta]. Non-selective beta blockers can make respiratory 
symptoms in patients with asthma or bradycardia much worse, and can cause 
bronchospasm, headache, dizziness, or hypotension [Schwarzt, Gupta]. 
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Cardiovascular function in patients can also be adversely affected through the 
systemic absorption of these medications since beta blockers decrease cardiac output 
[GRF]. "These agents should be used with caution in any patient with heart disease, 
heart block, or cardiac failure" [Vetrugno]. Systemic side effects of beta blockers can be 
minimized if patients close their eyes after application or use a technique called punctal 
occlusion, which prevents medication from entering systemic circulation through the tear 
drainage ducts [GRF]. In patients with diabetes, the symptoms of hypoglycemia may be 
hidden by the use of beta blockers. Long term effects associated with the use of beta 
blockers include mood alterations, hallucinations, memory loss, impotence, and loss of 
exercise tolerance. 
The effectiveness of all the beta blockers in lowering IOP is similar, even though 
their structures differ. On average, timolol reduces IOP by 20-35% [Gupta]. Beta 
blockers such as carteolol and levobunolol tend to reduce side effects because they also 
mimic sympathetic nervous system activity. Carteolol showed a median decrease in IOP 
of 22-25% during clinical trials, and did not cause painful stinging or irritation in patients 
during application. A major issue with beta blockers is the fact that they are not as 
effective at night in lowering IOP and can cause nocturnal arterial hypotension, 
potentially leading to quicker visual field loss in susceptible individuals [Hayreh]. 
Overall, though beta blockers effectively lower IOP their use as a monotherapy for 
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glaucoma has decreased significantly in recent years due to their systemic and ocular side 
effects. 
B.2. Prostaglandin Analogs 
Prostaglandin analogs are thought to increase the outflow of ocular fluid through 
the less commonly used uveoscleral pathway, by altering the local permeability and 
pressure gradients [Gupta]. Due to their mechanism of action they tend to be more 
effective in patients with open angle glaucoma [GRF]. All the prostaglandins are partial 
agonists of the FP prostanoid receptor with the exception of travaprost, which is a full 
agonist. Several different medications on the market include travaprost, bimatoprost, and 
latanoprost. Latanoprost was introduced in 1996 as the first prostaglandin analog on the 
market, after which it eventually has become one of the most popular prescribed 
treatments for glaucoma. 
Initially prostaglandins were not marketed for use on glaucoma patients because 
they caused inflammation, but after modification to the molecule the inflammation was 
reduced while the IOP lowering properties were maintained. The major benefit of using 
prostaglandins is that they have very few systemic side effects, mainly due to their rapid 
elimination half-life, though a few patients reported headaches, flu-like symptoms, and 
muscle pain [Vetrugno]. Prostaglandins do have ocular side effects, including changing 
pigmentation/darkening in the eye, growth of eyelashes, stinging, itching, burning, 
conjunctiva! hyperemia and blurred vision. 
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All of the prostaglandin analogs have similar safety profiles, and all of them are 
just as effective as beta blockers, lowering IOP about 20-35% from baseline [Vetrugno]. 
Prostaglandin analogs are effective at low concentrations, with the typical concentration 
of latanoprost and travaprost medications around 0.004%. At very high doses they can 
cause an increase in IOP, so care must be taken to ensure correct dosing. In addition to 
lowering IOP, some prostaglandin analogs have been found to increase microcirculation 
in the optic nerve head, which could potentially help protect the cells of the optic nerve 
from damage [Gupta]. A benefit ofprostaglandin analogs over beta blockers is they do 
not become less effective at nighttime and are stable compounds that do not usually 
require refrigeration. Also, prostaglandins typically only require one application per day, 
which helps improve patient adherence. Due to their numerous positive qualities and 
minimal side effects, prostaglandin analogs are used to treat roughly 35% of glaucoma 
cases [Stein]. A possible issue with prostaglandins is that they cost slightly more than 
other treatments, with latanoprost averaging $350 per year for patients [Vold]. 
Prostaglandins are definitely a promising newer class of drugs for the treatment of 
glaucoma. 
B.3. Adrenergic Agonists 
Adrenergic agonists lower IOP by increasing aqueous humor outflow through 
both the trabecular meshwork and uveoscleral pathways [Gupta]. With the use of general 
adrenergic agonists, both the beta and alpha adrenoreceptors in the eye are stimulated. 
The main adrenergic agonists used for the treatment of glaucoma are epinephrine and 
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dipivefrin. Dipivefrin is a prodrug of epinephrine that does not require as high of a 
dosage because the addition of lipophilic functional groups allows it to more easily 
penetrate the cornea. Epinephrine lowers IOP by 15-25% while dipivefrin lowers IOP by 
20-24%. Ocular side effects of using adrenergic agonists include blurred vision and 
conjunctival hyperemia, while systemic side infects include headaches, heart palpitations, 
high blood pressure, and anxiety [GFR]. The use of these epinephrine compounds has 
decreased in recent years, going from 16% of glaucoma cases in 1992 to only 0.6% in 
2002 [Stein]. 
Alpha-2 adrenergic agonists used for the treatment of glaucoma include clonidine, 
apraclonidine and brimonidine. These medications decrease aqueous humor production 
while slightly increasing aqueous humor outflow. Alpha agonists are relatively selective 
to the alpha-2 adrenergic receptors, with some activity at the alpha-1 adrenergic 
receptors. Apraclonidine and brimonidine both have similar efficacies in lowering IOP, 
giving a 20-27% reduction in IOP [Gupta]. Also, brimonidine has a potential 
neuroprotective effect that could prevent deterioration of the retinal ganglion cells 
[Robin]. Though these medications sufficiently lower IOP, the necessity of two or three 
applications a day can adversely affect patient adherence. 
The alpha-2 specific agonists overall have less side affects than the non-specific 
ones. Clonidine was the first alpha agonist used, but due to concerns of arterial 
hypotension and decreased blood flow to the optic disk more specific alpha agonists were 
developed [Vetrugno]. Brimonidine is around 30 times more selective for the alpha-2 
receptor and is more lipophilic than the other alpha agonists, which increases its diffusion 
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through the cornea [Schuman]. Unlike clonidine, brimonidine cannot cross the blood-
brain barrier and therefore has less systemic side effects. Burning and stinging of the 
eyes with application along with an allergic reaction leading to conjunctivitis are possible 
side effects of using alpha agonists [GRF]. 
In addition, some patients report fatigue, irritability, headaches, dry mouth, and 
dry nose with the use of alpha agonists. Alpha agonists, in particular apraclonidine, can 
become ineffective after prolonged use because of increased drug tolerance, or 
tachyphylaxis [Gupta]. For this reason, some alpha agonists are only indicated for short-
term use. Alpha agonists were first introduced in 1996, and their use peaked in 2000 at 
treating 22% of glaucoma cases after which their use decreased to treating 17% of 
glaucoma cases by 2002. On average, brimonidine costs roughly $270 a year for patients 
[Vold]. Though alpha agonists are currently fairly common, their utilization is 
decreasing as more medications with fewer side effects are developed. 
B.4. Carbonic Anhydrase Inhibitors 
There are two types of carbonic anhydrase inhibitors (CAls) that are utilized for 
the treatment of glaucoma: Topical CAis and Systemic/Orally delivered CAis. Carbonic 
anhydrase inhibitors function by decreasing aqueous humor production. The reaction 
converting water and carbon dioxide to a proton and bicarbonate is an essential step in 
the production of aqueous humor that is catalyzed by the carbonic anhydrase enzyme. 
The carbonic anhydrase enzyme's function is stopped by the use of the CAis, thereby 
slowing aqueous humor production and lowering IOP. Commercially available drugs 
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include acetazolamide or methazolamide pills, and dorzolamide or brinzolamide eye 
drops [Gupta]. A 16-26% reduction in IOP is observed with dorzolamide, and CAis may 
have the added benefit of increased ocular blood flow [Vetrugno]. The frequency of 
administration, three times a day for dorzolamide, may cause poor adherence in patients 
with CAis as part of their regimen. 
The systemic CAis have many more adverse side effects than the topically 
delivered CAis. Oral CAis can cause fatigue, tingling in the extremities, weight loss, 
depression, upset stomach, aplastic anemia, and kidney stones. The side effects of topical 
CAis are less severe and include things such as stinging and burning sensations in the 
eye. Some patients experience an allergic reaction to topical CAls, which can induce 
conjunctivitis. Brinzolamide causes less ocular discomfort than dorzolamide because it is 
more lipophilic and can more easily cross the cornea [Vetrugno]. 
Oral CAis were used to treat 9% of glaucoma cases in 1992, a number that 
decreased to 2% by 2002 because of the very severe systemic side effects [Stein]. 
Topical CAis were first introduced in 1998, after which they peaked at treating 11 % of 
cases in 1999, a number that decreased to 6% by 2002. Frequently topical CAis are 
combined with beta blockers, a treatment used for 10% of glaucoma cases by 2002. 
Dorzolamide costs approximately $280 per year while brinzolamide costs around $240 
per year [Vold]. Timolol combined with dorzolamide costs $470 per year, which is a 
barrier for its use in patients with less money. Systemic CAis have a great deal of 
harmful side effects, but topical CAis are both safe and effective medications for treating 
glaucoma. 
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B. 5. Parasympathomimetic Agents/Cholinergics/Miotics 
Miotics were introduced in 1870, and were the first class of medication used for 
the treatment of glaucoma [Dietlein]. Parasympathomimetic agents lower IOP by 
increasing aqueous humor drainage through the trabecular meshwork. The increased 
outflow is achieved when the anterior chamber angle is widened due to the contraction of 
the pupil and action of the ciliary muscle. Pilocarpine, aceclidine, carbachol, and 
acetylcholine are different cholinergic agents on the market. The reduction in IOP with 
the use of cholinergic agents is comparable to that obtained with the use of timolol. Due 
to the short duration that miotics remain effective they need to be administered four times 
per day, a number that greatly reduces patient compliance. 
The negative impact of cholinergic agents caused their use to greatly decline in 
recent years, despite their low cost and high efficacy [Schwarzt]. Bronchospasm, cardiac 
irregularities, and intestinal cramps can result from the use of cholinergic agents. 
Locally, miotics can cause extreme pupil constriction, brow ache, myopic shift, 
inflammation of the iris, and increased risk of retinal detachment. Thickening of the 
conjunctiva, cataracts, abnormal increase in tear production, and stinging are other 
possible side effects associated with the use ofmiotics [Vetrugno]. The use of 
cholinergic agents sharply declined between 1992 and 2002, going from 28% of 
glaucoma cases in 1992 to only 4% of glaucoma cases in 2002 [Stein]. Miotics are the 
oldest form of glaucoma treatment and have been the mainstay for years, but they have 
recently fallen out of favor due to their numerous harmful ocular side effects. 
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B. 6. Hyperosmotic Agents and Investigational Medications 
Hyperosmotic agents are used to temporarily lower extremely high IOPs. The 
hyperosmotic agents work by reducing the overall fluid volume in the eye. An osmotic 
gradient is created between the ocular fluids and the blood, causing aqueous humor to 
drain from the anterior chamber [Kolker]. Oral glycerol, isosorbide, and intravenous 
mannitol are commercially available hyperosmotic agents. Glycerol can cause nausea 
and vomiting, while pulmonary edema and congestive heart failure are severe 
complications that can result from the use of hyperosmotic agents. In cases of acute 
glaucoma hyperosmotic agents are very effective. 
Numerous new drugs are being investigated for their potential efficacy and safety 
in the treatment of glaucoma. An increased glutamate level has been implicated in the 
progression of glaucoma because it increases intracellular calcium, resulting in cell death 
[Gupta]. Novel treatments looking into glutamate inhibition are currently under 
consideration. NMDA antagonists could protect the RGCs by blocking increase in 
glutamate. Memantine and eliprodil are two NMDA antagonists currently being studied 
for their efficacy in preventing RGC destruction [Robert]. 
The ability of a patient to resist visual loss at higher IOPs largely depends on their 
specific immune response. Recent studies have looked into vaccines that could 
potentially protect the RGCs from future damage. Rl6 is a peptide obtained from the 
RGCs that could potentially be used to vaccinate the eyes against !OP-induced RGC loss 
and that has shown promise in animal models [Bakalash]. Erythropoietin, caspase 
inhibitors and iNOS-2 inhibitors are other potential glaucoma treatments [Gupta]. 
Mineralocorticosteroids such as fludrocortisone, and calcium antagonists such as 
nimodipine or nifedipine have also been proposed for glaucoma therapy [Dietlein]. 
Appendix C: Other Conventional Surgeries and Laser Surgeries 
C. J. Trabeculotomy and Goniotomy 
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Another type of glaucoma surgery is a trabeculotomy. In a trabeculotomy an 
incision is made in the trabecular meshwork to increase aqueous humor outflow 
[Dietlein]. A portion of the trabecular mesh work is not removed during a trabeculotomy 
as it is during a trabeculectomy. Also, an ab intemo trabeculotomy "avoids the creation 
of a subconjunctival bleb associated with traditional trabeculectomy" [Sloan]. In a non-
randomized comparative study, the success rate (defined as a final IOP less than 21 mm 
Hg, 20% reduction in IOP after 3 months, and no need for additional glaucoma surgery) 
oftrabeculotomy ab intemo was 65% [Sloan]. Using an IOP below 21 mm Hg as the 
only measure of success, another smaller experiment showed a success rate for the ab 
intemo trabeculotomy procedure of91 % at the 24 month follow-up. Patients still had to 
take medication following the ab intemo trabeculotomy, though the average number of 
medications decreased from 3 to 1 on average. With all types of glaucoma surgery 
patients often need to continue using pharmaceutical agents in order to maintain a lower 
IOP. 
Goniotomy is another type of glaucoma surgery during which the trabecular 
mesh work is surgically opened. During a goniotomy, the surgeon goes in through the 
cornea to make incisions along the anterior trabecular meshwork in a 90 to 120 degree 
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arc [Azuara-Blanco]. The main difference between a goniotomy and a trabeculotomy is 
that the trabecular mesh work is reached from inside of the anterior chamber during a 
goniotomy, but from outside of the anterior chamber during a trabeculotomy. Along with 
trabeculotomy, goniotomy is the preferred method for treating congenital glaucoma 
[Dietlein]. "Although successful in infant eyes with abnormally developed meshwork, 
goniotomy and trabeculotomy have been generally disappointing in adult eyes" [Johnson 
2001]. Goniocurettage, similar to a goniotomy, is a promising newer procedure during 
which part of the trabecular mesh work is scraped away in a 90 degree arc with a curette. 
C.2. Full Thickness Procedures 
Several penetrating, full thickness procedures that can be used for the treatment of 
glaucoma are: an anterior lip sclerectomy, posterior lip sclerectomy, trephination, thermal 
sclerostomy, conventional sclerostomy, enzymatic sclerostomy, or iridenclesis [Nutan]. 
In a sclerectomy a full thickness portion of the sclera is entirely removed, usually with a 
punch, from the limbal portion of the sclera near to the cornea [Stamper 2009]. In the 
posterior lip sclerectomy, which is preferred by most surgeons over the anterior lip 
sclerectomy, the placement of the ab extemo incision is slightly different than in the 
anterior approach and the tissue is removed from the back portion of the incision instead 
of the front portion of the incision. 
Using an electrocautery tool in order to create an opening into the anterior 
chamber angle from the limbus is how a thermal sclerostomy is performed. The success 
rate of the thermal sclerostomy and the posterior lip sclerectomy was found to be the 
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same in a comparative study [Marion]. A trephination is where a fistula is created in the 
limbal area of the sclera near to the cornea using a trephine, which is a cylindrical 
surgical tool that can remove tissue sections [Stamper]. During an iridenclesis, part of 
the iris is pulled outwards from the anterior chamber and confined in the scleral sulcus 
incision. "The presumed mechanism was a 'wicking' of the aqueous by the iris tissue" 
[Stamper]. However, there are many complications with a iridenclesis, including chronic 
inflammation of the iris, infection, and sympathetic ophthalmia (inflammation of both 
eyes following trauma to one eye). Full thickness procedures are typically avoided due to 
their severe side effects. 
Another type of glaucoma surgery called an iridotomy involves an incision of the 
iris to allow better aqueous humor outflow. Similar to an iridotomy, an iridectomy is a 
glaucoma filtration surgery during which a section of the iris is removed. The iridectomy 
procedure was first introduced in the 19th century, and is the oldest surgical treatment of 
glaucoma [Dietlein]. Iridotomy and iridectomy are typically used to treat patients 
suffering from angle closure glaucoma [ Amerasingh]. In addition, a peripheral 
iridectomy is a routine part of many filtration procedures, including trabeculectomy. 
However, recent studies show that a peripheral iridectomy during a trabeculectomy 
should be avoided because it can cause more complications without any additional 
lowering oflOP [De Barros]. Though the laser version of an iridotomy is typically 
preferred because it is "less traumatic, associated with fewer complications, and can be 
performed on an outpatient basis," recent studies have shown that "small incision surgical 
iridectomy can be minimally invasive and effective" [Finger]. In certain cases of 
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glaucoma, a ciliarotomy or ciliectomy could be performed to either divide or remove 
sections of the ciliary body, thereby reducing the amount of aqueous humor production. 
C.3. Laser Trabeculoplasty 
Laser surgery is typically not as effective as conventional surgery in counteracting 
the elevated IOP seen in glaucoma patients, but it is much safer and does not have as 
many adverse side effects. One type of laser surgery commonly used is called laser 
trabeculoplasty. During this procedure a laser is directed at the angle of the eye to burn 
sections of the drainage channels and open them up to allow for better aqueous humor 
outflow [Mayo Clinic]. Some patients report a stinging sensation during laser treatment, 
so a topical anesthetic is typically used prior to surgery to reduce any discomfort [GRF]. 
Argon laser trabeculoplasty and selective laser trabeculoplasty are the two main types of 
laser therapy used for the treatment of glaucoma [GRF]. In argon laser trabeculoplasty a 
high energy laser is used to treat some of the filtration channels. 
Selective laser trabeculoplasty (SLT) uses a low energy Nd: Y AG laser to 
selectively treat certain areas of the outflow pathway while leaving the rest intact. 
Selective laser trabeculoplasty is very safe due to the low energy levels of the laser. 
Additionally, SLT has been shown to be just as effective as argon laser trabeculoplasty. 
If the IOP is not lowered sufficiently after the first treatment, the patient can undergo 
more laser treatments. Two sessions of laser trabeculoplasty are typically used. A 20% 
reduction in IOP is seen in 60% to 80% of patients who have undergone selective laser 
trabeculoplasty, though some studies show much lower success rates [Nagar, Dietlein]. 
Laser trabeculoplasty is typically only used for patients during the earlier stages of 
glaucoma because it only reduces IOP 5-6 mm Hg on average. 
C.4. Laser Iridotomy and Laser Cyclophotocoagulation 
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A laser iridotomy is another surgical procedure that can be used to lower IOP 
[Mayo Clinic]. During this procedure a laser is used to create a hole in the iris and 
release pressure beneath the iris. This procedure was introduced in the 1970s, and it had 
a high failure rate of around 20% with a high closure rate of 30% when performed with 
an argon laser [De Silva]. The procedure has since undergone several modifications to 
improve efficacy and prevent serious complications such as hemorrhage of the iris. 
Today a Nd:YAG laser is used to perform this procedure, though an argon laser is 
sometimes also used in patients with darker eyes. Laser iridotomy is mainly used in 
patients with narrow or closed angles, and additional therapy is often necessary to control 
IOP for many patients with chronic open angle glaucoma. Complications of a laser 
iridotomy include corneal damage, cataract formation, hemorrhage, retinal bums, IOP 
spikes, or malignant glaucoma. An argon laser iridoplasty is another procedure which 
"involves the placement of a ring of contraction bums on the peripheral iris to contract 
the iris stroma near the angle, mechanically pulling open the angle" and lowering IOP 
[ Amerasingh]. 
Laser cyclophotocoagulation is a procedure that uses a laser in order to destroy 
the epithelial cells of the ciliary body that produce aqueous humor [Dietlein]. The cells 
in the ciliary body are coagulated using a laser aimed from either inside the eye using an 
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endoscope or from outside the eye through the sclera, where no incision is necessary. 
Excessive treatment with this therapy can cause phthisis bulbi, or the shrinkage of the 
eye. Knowing the proper amount of treatment to apply during cyclophotocoagulation 
therapy is difficult, however, because a clear relationship between the amount of 
treatment and its effect on lowering IOP has not been established. The effectiveness of 
this procedure has yet to be concretely shown, and there is still controversy on the value 
of this treatment. 
A recent retrospective study that reviewed cyclophotocoagulation showed that the 
treatment does have some promise and concluded that "diode laser 
cyclophotocoagulation is an efficient treatment for refractory glaucoma" [Iliev ]. In the 
study, success (IOP between 6 mm Hg and 21 mm Hg) was seen in 69.5% of patients, 
failure or non-response was seen in 13% of patients, and hypotony was seen in 17.5% of 
patients. On average, the IOP went from 36.9 mm Hg before treatment to 15.3 mm Hg 
after treatment. Other studies have shown that severe vitreoretinal complications can 
occur following cyclophotocoagulation, including retinal detachment, choroidal 
neovascularization, endophthalmitis and vitreous haze [Wagenfeld]. More research 
needs to be conducted in order to be able to safely and effectively use 
cyclophotocoagulation as a glaucoma therapy since preliminary studies seem to indicate a 
high failure rate. 
Appendix D: Traditional Glaucoma Drainage Devices 
D.1. Molteno Implants 
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Molteno implants were introduced and 1969 as some of the first open-tube shunts 
for the treatment of glaucoma. Earlier in history setons, or solid stents that act like a 
wick, were used for the treatment of glaucoma and were made out of materials such as 
silk, cartilage, platinum, gold, or silicone [Stamper 2009]. The Molteno implants are 
made out of polypropylene and come in 135 mm2 area single plate or 270 mm2 area 
double plate configurations. A newer version of the Molteno implant, the Molteno 3 
shunt, is both flexible and larger than the conventional design and can be either 175 mm2 
or 230 mm2 in area [Shaarawy]. The shunt looks like a tube connected to a flat disk at 
one end. The tube enters the anterior chamber and bypasses the normal drainage 
pathways, shunting aqueous humor into a reservoir provided by the acrylic end plate. 
Several studies on the potential advantages of using more plates in the Molteno 
implant have shown that more plates allow for greater aqueous filtration, but with a 
higher risk of postoperative hypotony [Molteno, Sherwood, Minckler]. One study 
showed that the double-plated Molteno implant had a success rate of 80% at one year, 
where success was defined as an IOP between 5 and 15 mm Hg [Taglia]. Another study 
on the use of the Molteno implant for neovascular glaucoma showed that it "provides 
useful long-term visuat results in 39% of cases" [Every]. When compared with a 
trabeculectomy, patients with the Molteno implant had an average IOP of 15.4 mm Hg 
while patients with the trabeculectomy had an average IOP of 16.1 mm Hg at their 6 
month follow-up, with different types of complications seen in both groups [Bluestein]. 
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A variation of the Molteno implant called the Schocket procedure "involves shunting of 
aqueous via a tube to an encircling band" [Stamper 2009]. Though "results with the 
Schocket implant are similar to those with the Molteno implant, ... most authors report 
slightly higher complication or reoperation rates" [Stamper 2009]. 
D.2. Baerveldt Implants 
Baerveldt implants are made from silicone and come in two sizes, either 250 mm2 
or 350 mm2• According to the designers and manufacturers of the valve, its ''unique 
fenestrations allow the growth of fibrotic tissue through the fenestrations, thereby 
'riveting' the bleb to the sclera" [Abbott]. Also, the device is "designed to control bleb 
height and volume" along with "minimizing the potential for ocular motility 
disturbances" [Abbott]. There is an optimum surface area for these shunts, determined 
through many different studies. In one study, a 500 mm2 Baerveldt device was 
determined to be too large because it did not perform as well as a 350 mm2 device, with a 
5-year success rate of 66% compared with a 5-year success rate of 79% for the smaller 
device [Britt]. Another study showed very little difference between IOP reduction of the 
250 mm2 device and IOP reduction of the 350 mm2 device at almost 3 years after 
implantation in people of Asian descent [Seah].· 
Based on these and other previous studies, an implant size between 250 mm2 and 
350 mm2 seems to be the most effective compromise between fibrous encapsulation and 
overfiltration. Despite the potential long term benefits of using a larger implant, many 
surgeons prefer to use the smaller implants to allow for easier shunt insertion and to 
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avoid the risk ofhypotony seen with the larger implants [Shaarawy]. The highest success 
rate shown for this valve was 96% at one year following surgery (where success was 
defined as an IOP less than 21 mmHg and an IOP more than 20% below baseline), with 
an average IOP of 12.4 mm Hg [Gedde]. 
D.3. Krupin Valve 
The Krupin valve is a device made from a silicone elastomer. It is a 13 x 18 mm 
oval that is 184 mm2 in area [Shaarawy]. "The end of the tube has a four-leaflet valve 
that eliminates the need for a stent or ligating suture during the early postoperative 
period" and prevents hypotony [Burchfield]. Though the valve is useful in preventing 
overfiltration, it is prone to malfunction and blockage. One study that required surgical 
revision following implant failure in 7% of patients concluded that the valve could be 
later modified to improve outflow in a relatively safe manner. 
Another study looking at the long-term results of the Krupin valve showed a 3 
year success rate of 66% and a 6 year success rate of 34%, where success was defined as 
an IOP between 5 and 22 mm Hg without additional glaucoma filtering surgery or 
devastating complications [Mastropasqua]. In the same study 54% of the patients 
experienced hypotony immediately after surgery, while 43% experienced external 
conjunctiva! bleb failure and 18% experienced blockage of the shunt by fibrovascular 
tissue in the long term. These results showed that "postoperative early hypotony, the 
growth of fibrovascular tissue extending to the open end of the anterior chamber and 
eternal scarring of the conjunctiva! bleb are the three most common causes of failure of 
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valve implants in filtering surgery" [Mastropasqua]. Another comparative study with 
more stringent IOP criteria showed the Krupin valve had a one year success rate (defined 
as an IOP between 5 mm Hg and 15 mm Hg) of only 39% [Taglia]. 
D. 4. Ahmed Valve 
An Ahmed valve is another glaucoma drainage device. It comes in a 184 mm2 
area single plate or a 364 mm2 area double plate configuration. The designers of the 
valve state that the Ahmed valve "utilizes a specially designed, tapered trapezoidal 
chamber to create a Venturi effect to help aqueous flow through the device" and reduce 
valve friction, along with elastic membranes that can change shape to help regulate fluid 
flow consistently [New World Medical]. The Ahmed valve can be made from either 
polypropylene or silicone. Several were conducted in order to determine if the material 
made a difference in overall outcome. One study showed that both polypropylene and 
silicone had the same effect on pressure, but with less complications related to the 
polypropylene valve, while another study showed that silicone had a greater IOP-
lowering effect [Shaarawy, Law]. 
It seems that the material that a shunt is made of can have an impact on its long-
term efficacy, but more studies need to be done to elucidate the exact impact of the 
material on patient outcomes. When compared to a double-plate Molteno implant and the 
Krupin eye valve, "the Ahmed implant is less likely to create problems leading to 
reoperations or visual acuity loss than the Molteno or Krupin implants" [Taglia]. A 
recent study comparing the Ahmed valve to a trabeculectomy concluded that the 5-year 
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success rates (with success defined as an IOP less than 21 mm Hg and an IOP more than 
15% below base line) of both procedures were not significantly different [Tran]. 
Figure D.1 Pictures of the Ahmed valve (top left), Baerveldt implant (top right), and 
Molteno implant (bottom) [New World Medical, Abbott, MedCompare] 
D.5. Comparisons of Ahmed and Baerveldt Implants 
There are a great deal of studies comparing the Ahmed valve and Baerveldt shunt, 
all showing varying outcomes. One study showed almost identical 4 year success rates 
(where success is defined as an IOP between 6 and 21 mm Hg with no additional 
glaucoma surgery needed and no devastating complications) of 62% in the Ahmed valve 
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group and 64% in the Baerveldt implant group, though patients with the Ahmed valve 
required more medication to control their IOP [Tsai 2006]. A different experiment 
concluded that "the Baerveldt-350 implant and the Ahmed valve had similar IOP control 
and surgical outcomes in patients with refractory glaucoma at I-year follow-up," with a 
surgical success rate of 65.6% for both (where success is defined as an IOP between 6 
and 22 mm Hg but also greater than 30% below baseline) [Syed]. 
The Baerveldt implant had a success rate (defined as an IOP ofless than 22 mm 
Hg with no medication at the last follow-up visit) of 83.3% while the Ahmed valve had a 
success rate of 66.7% after 6 months in a smaller study on Asian patients [Wang]. 
Another more recent experiment also provided evidence that the "Ahmed S2 glaucoma 
valve may be less effective at lowering IOP than the Baerveldt 250-mm2 Glaucoma 
Implant" [Goulet]. In this study, where success was defined as an IOP between 5 and 22 
mm Hg with at least a 20% reduction in IOP, the Baerveldt group had a success rate of 
85% while the Ahmed group had a success rate of 62% at the two year follow-up, along 
with a lower mean IOP and lower number of medications on average. Valved and non-
valved devices seem to be equally effective in lowering IOP, but there are many factors 
that are difficult to account for during comparisons that affect the outcomes, including 
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